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Abstract 
 
 
Pyruvate dehydrogenase kinase 4 (PDK4), a mammalian mitochondrial serine kinase 
has emerged as an interesting candidate for diabetes therapy. Due to the high 
prevalence of this disease especially type 2 diabetes (T2D) and the health 
complications associated with it, there is extensive effort to find the appropriate 
treatment. Understanding the regulation of PDK4 would therefore contribute 
significantly to the development of therapeutic agents.  
 
This research outlines the bioinformatics analysis of PDK4, using tools such as 
Interweaver, ClustalW and Protein Structure Visualiser. These programs were used to 
determine potentially interacting partners for PDK4. Interweaver database identified 
96 proteins which have possible interaction sites for PDK4. Protein p100/p49, 
containing a death domain that is known to have a role in suppressing apoptosis, was 
identified as a potential partner for PDK4. The alignment between p100/p49 primary 
sequence and that of PDK4 using Gene explorer/ClustalW demonstrated sequence 
similarity between the two proteins. Swiss PDB Viewer then located the positions of 
the amino acids that are in the hypothetical protein binding motif of p100/p49 within 
the 3D structure of hPDK4. These amino acids were found to be located in the region 
of PDK4 which is known to bind protein substrates of PDK4 and may be accessible to 
other proteins as well. These findings were very interesting as PDK4 have not 
previously been associated with apoptosis and this could be the link between 
apoptosis and insulin resistance.  
 
 
 
  iv 
Cell biology studies were then performed to verify the relationship between PDK4 
and apoptosis. In this regard, HeLa and HepG2 cells were treated with apoptosis 
inducing agents such as TNFα, C2-Ceramide, and Linoleic acid. These cells were then 
monitored for apoptosis and PDK4 mRNA expression using a DNA laddering assay 
as well as Real Time PCR. The results showed that these factors to induce apoptosis 
in a concentration dependent manner. This induction of apoptosis by these three 
factors indicated to suppress PDK4 mRNA levels. These findings suggested a 
regulatory role for PDK4 in apoptosis. 
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CHAPTER 1 
 
1 Introduction 
 
 
Diabetes also known as diabetes mellitus is a disease that has been known to exist for 
thousands of years and affects approximately 6% of the world population. It is a 
metabolic disorder characterised by a failure to maintain glucose homeostasis and this 
results in a variety of severe complications (Malecki, 2005 and Nir and Dor, 2005). 
These complications which includes blindness, stroke, and renal insufficiency may 
arise due to the disease being undiagnosed or poorly controlled (Malecki, 2005). 
Diabetes in most patients is brought about by a combination of genetic and 
environmental factors (Accili, D, 2000). There are two main types of diabetes namely 
type 1 (T1D) and type 2 diabetes. (T2D) T1D diabetics frequently have very low 
insulin levels and depend on insulin intake for survival. The onset of the disease 
usually occurs at a young age but also may occur at any age (Fatehi-Hassanabad and 
Chad, 2005). T1D which accounts for 5-10% of diabetic cases results from 
autoimmune-mediated destruction of pancreatic β cells (Accili, 2000, Behrooz and 
Bobby, 2007 and Fatehi-Hassanabad and Chad, 2005). 
 
Type 2 diabetes mellitus (T2D), also known as non-insulin dependent diabetes 
(NIDDM) affects approximately between 2-6% of the adult population mostly in 
Western countries (Bailey, 2000). It manifests itself in middle or later stages of life 
and is growing rapidly worldwide (Korc, 2003). Approximately 85% of diabetic 
patients have T2D (Owen and Hattersley, 2001). Its chronic complications are a 
leading cause of death in many countries. T2D is caused by insulin resistance which 
results from the inability of tissues to respond to insulin (Goldstein, 2003; Metzler et 
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al., 2002; Withers et al., 2000 and Florence and Yeager, 1999). Lack of tissue 
response causes continuous secretion of insulin by pancreatic β cells, which results in 
β cell failure and a subsequent inability to synthesize and secrete insulin, whose 
primary biological function is to regulate and maintain glucose homeostasis (Quon, 
2001; Rasouli et al., 2005; Kahn, 2003; Goldstein, 2003 and Kawasaki, et al., 2004). 
Insulin resistance is normally caused by obesity and stress and is frequently associated 
with a number of diseases including chronic infection and hypertension (Korc, 2003; 
Bavenholm et al., 2003; Hunter and Garvey, 1998; Baumann and Saltiel, 2001; 
Banadonna et al., 1990). The resistance results from mutations or post translational 
modification of the insulin receptor or any of its downstream effector molecules (Le 
Roith and Zick, 2001 and Storz et al., 1999). 
 
Due to high prevalence of T2D and its health complications, there is intensive effort 
to find appropriate treatment. Pyruvate dehydrogenase kinase 4 (PDK4) has emerged 
as an interesting candidate in diabetes therapy (Sugden and Holness, 2002). 
Understanding its regulation would contribute meaningfully to this effort. We 
therefore sought to investigate the role of protein-protein interaction in the regulation 
of PDK4 activity.  
 
1.1 Physiological role of PDK4  
 
 
PDK4 is a member of a family of mitochondrial serine kinases that are more related to 
bacterial histidine kinases than eukaryotic serine kinases (Roche et al., 2001 and Gudi 
et al., 1995). All members of this family contain conserved motifs that form the 
kinase domain (Rowles et al., 1996). These kinases are involved in glucose clearance 
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by regulating the activity of pyruvate dehydrogenase complex (PDC) (Randle, 1986 
Patel and Roche, 1990 and Sugden and Holness, 2003). PDC is a multi-subunit 
enzyme composed of multiple copies of three catalytic enzymes pyruvate 
dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide 
dehydrogenase (E3) (Korotchkina and Patel, 2001). The E1 component is a 
heterotetramer composing of two α and two β which requires a thiamine 
pyrophosphate for its functioning (Korotchkina and Patel, 2001). Its α-subunit has 
three phosphorylation sites, site 1 (Ser-264), site 2 (Ser-271) and site 3 (Ser-203) 
(Korotchkina and Patel, 1995). The primary role of PDC is to catalyze the oxidative 
decarboxylation of pyruvate to form acetyl-CoA and to reduce NAD+ to NADH, a 
rate limiting step in glucose metabolism (Kolobova et al., 2001). The reaction 
catalysed by PDC is depicted in the schematic diagram below in figure 1: 
 
Pyruvate dehydrogenase kinases (PDKs) inactivate PDC by phosphorylation of the 
serine residues on the E1 α-subunit of PDC (Yeaman et al., 1978 and Korotchkina and 
Patel, 2001). Currently, four PDK isoforms have been identified in humans, PDK1, 2, 
3 and 4 (Bowker-Kinley et al., 1998). These isoforms are known to perform similar 
functions due to strong conservation of their primary structure even though they are 
expressed differently in different cell types (Bower-Kinley et al., 1998 and Popov, 
1993).  
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Glucose
Pyruvate
Pyruvate + CoA + NAD+ Acetyl-CoA + NADH + CO2
PDC
PDK (1-4)
Cytosol
Mitochondrial
matrix
 
Figure 1. A schematic diagram showing the regulation of PDC by PDKs. PDC 
catalyses the oxidative decarboxylation of pyruvate to acetyl CoA and reduces NAD+ 
to NADH. PDC activity is inhibited by PDKs through phosphorylation (as indicated 
by a bar).  
 
1.2 Regulation of PDK4 
 
The activity of PDK4 is known to be regulated by short-term (Wieland and Siess, 
1971) and long-term (Dennis et al., 1978) mechanisms. In the short-term, the activity 
of the PDK enzyme is modified by factors that bind to the PDK protein, whereas, the 
long-term regulation of PDK is achieved by controlling PDK gene expression. 
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1.2.1 Regulation of PDK enzyme activity 
 
The short-term regulation of PDK has been studied primarily in rat PDK2 which has 
very high structural similarity to PDK4. These studies revealed that substrates and 
products of the PDC action regulate PDK activity via allosteric mechanisms (Pratt and 
Roche, 1979). For example, PDC substrates which include pyruvate, NAD+ and 
coenzyme A (CoA) were shown to inhibit PDK activity (Sugden and Holness, 2002 
and Kolobova et al., 2001), and the PDC products such as NADH and acetyl-CoA 
were shown to induce PDK activity as illustrated in figure 2 (Kerbey et al., 1979).  
 
Mitochondrion Cytosol
Pyruvate + CoA + NAD+ Acetyl-CoA + NADH + CO2
PDC
PDK (1-4)-
Pyruvate
Glucose
Glucose
Glycogen
LC-CoA
FFA
FFA
Acetyl CoA
Citrate Citrate
 
 
Figure 2. Regulation of PDK enzyme activity.  Solid arrows indicate biochemical 
pathways, dashed arrows indicate positive regulation of enzyme activity, and the 
dashed bars indicate suppression of enzyme activity. 
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Fatty acid metabolism is known to increase PDK activity, presumably through 
production of acetyl-CoA (figure 2, Holness et al., 1989). Further, the interaction 
between PDC and PDK has also been shown to activate PDK (Korotchkina and Patel, 
2001).  
 
1.2.2 Regulation of PDK gene expression 
 
Long-term regulation of PDK is effected by nutritional and hormonal states (Wu et 
al., 1999; Huang et al., 1998 and Sugden et al., 1998), which regulate PDK activity 
by controlling PDK gene expression. The primary PDK isoform whose expression is 
affected by these factors is PDK4. Levels of PDK4 expression are elevated during 
starvation, high-fat feeding and diabetes (Wu et al., 1999, Wu et al., 1998 and Kwon 
and Harris, 2004). Hormones such as glucocorticoids have also been shown to induce 
PDK4 expression (Huang et al., 2002). In addition, it has been shown that insulin 
regulates the expression of PDK4 mRNA levels by suppressing it (Huang et al., 2002 
and Lee et al., 2004). Furthermore PDK4 gene expression has also been shown to be 
regulated by thyroid hormone, fatty acids, TNFα and ceramide (Kwon and Harris, 
2004). Recent studies have shown that estrogen related receptors (ERRs) also induce 
PDK4 gene expression in hepatic cells (Zhang et al., 2006). These ERRs bind to the 
PDK4 gene promoter therefore stimulating PDK4 gene expression. Factors that 
mediate PDK4 gene expression are known to activate several signal transduction 
pathways which are discussed below. 
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PDK 4 gene expression
Diabetes
Insulin
Thyroid Hormone
Estrogen receptors
Starvation
High fat feeding/
Fatty acids
Stress/ Glucocorticoids
 
Figure 3. Regulation of PDK4 gene expression.  Arrows indicate factors that induce 
PDK4 gene expression, and the solid bar indicates factors that suppress PDK4 gene 
expression. 
 
1.2.2.1 Signalling pathways activated by insulin 
 
Insulin plays a prominent role in the regulation of the metabolic clearance of glucose 
by utilizing the phosphatidylinositol 3 (PI3) kinase signalling pathway (Cheng et al., 
2002 and Baumann and Saltiel 2001), Figure 3). Binding of insulin hormone to the 
insulin receptor (IR) is necessary for initiation of this signalling (Formisano and 
Benguinot, 2001, White, 1997 and Kaburagi et al., 1993).  
 
The IR is a large transmembrane glycoprotein consisting of two α and β subunits 
which form a heterotetramer (Le Roith and Zick, 2001, Hunter and Garvey, 1998 and 
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Kahn and Goldfine, 1993). The α subunits are entirely extracellular and have been 
shown to interact directly with the ligand, whereas the β subunits are transmembrane 
proteins and have tyrosine kinase activity on the intracellular domains (Hunter and 
Garvey, 1998; Kahn and Goldfine, 1993 and Le Roith and Zick, 2001). Ligand 
binding to the extracellular α subunit induces conformational changes in the β 
subunits which result in activation of tyrosine kinase activity in the intracellular 
domain (Cheng et al., 2002 and Whitehead et al., 2000). This results in tyrosine 
phosphorylation of insulin receptor substrates (IRSs) (Whitehead et al., 2000; White, 
1997; Kahn and Goldfine, 1993; and Frattali et al., 1992) and activation of the PI3 
kinase pathway (Duan et al., 2004; Egawa et al., 1999 and Kahn and Goldfine, 1993). 
 
The PI3 kinase pathway regulates many of the enzymes that are utilized by insulin to 
stimulate the metabolic clearance of glucose. For example, activation of atypical 
protein kinase C (aPKC) by insulin through PI3 kinase stimulates glucose uptake by 
promoting the translocation of glucose transporter 4 (Glut 4) to the cell membrane 
(Whitehead, et al., 2000; Formisano and Beguinot, 2001 and Duan, et al., 2004). PI3 
kinase also promotes the conversion of glucose to glycogen by inhibiting glycogen 
synthase kinase3 (GSK3) (Pessin et al., 1999; Clark et al., 1998 and Uchida et al., 
2000). GSK3 is a physiologic inhibitor of glycogen synthase (Cross et al., 1995 and 
Pap and Cooper, 1998). The PI3 kinase dependent inhibition of GSK3 is mediated by 
Akt (Hunter and Garvey, 1998).  
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These observations are consistent with those reported by Cross et al., (1995), which 
demonstrated that Akt activation resulted in phosphorylation and inactivation of GSK-
3 which resulted in of glycogen synthase activity.  
 
The PI3 kinase pathway also promotes metabolic utilization of pyruvate by inhibiting 
the expression of PDK4 (Kwon, et al., 2004; Furuyama, et al., 2003; Egawa, et al., 
1999), the inhibitor of pyruvate dehydrogenase complex (Yeaman et al., 1978 and 
Korotchkina and Patel, 1995). This metabolic effect of PI3 kinase is also mediated by 
Akt, whose activation has been shown to lead to the phosphorylation of transcriptional 
factors known as Forkhead Box O factors (FOXO). The FOXO group consists of 
FOXO1a, FOXO3a and FOXO4 which are transcription factors that act downstream 
of Akt (Kwon et al., 2004). Two of these factors, FOXO1a and FOXO3a have been 
shown to bind on hPDK4 promoter through the insulin response elements (Kwon et 
al., 2004). Binding of these transcriptional factors to the promoter activates hPDK4 
gene expression. However, insulin action results in activation and phosphorylation of 
Akt, which leads to translocation of Akt from the cytoplasm to the nucleus where Akt 
phosphorylates FOXO transcription factors (Van der Heide and Smidt, 2005). The 
phosphorylation of FOXO results in reduction of DNA binding ability and FOXO 
translocation from the nucleus to the cytoplasm. This results in the inactivation of 
PDK4 gene expression (Kwon and Harris, 2004).   
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Figure 4. The mechanisms involved in the metabolic signalling pathway initiated by 
insulin action. IRS-insulin receptor substrate, GLUT4- glucose transport protein 4; 
GSK3- glycogen synthase kinase 3; PI3 kinase-phosphatidylinositol 3 kinase; aPKC – 
atypical protein kinase C; FOXO – Forkhead box factors. 
 
 
1.2.2.2 Signalling pathways activated by Fatty acids 
 
 
Fatty acid (FA) signalling has been the subject of interest for many years and it has 
been revolutionized by the discovery of a novel steroid hormone receptor that can be 
activated by both FAs and fatty acid-like molecules called peroxisome proliferators 
(PPs) (Issemann and Green, 1990). These receptors are known as peroxisome 
proliferators-activated receptors (PPARs). PPARs are recently classified into 
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subfamilies which include PPARα, PPARβ and PPARγ (Braissant, 1996), and these 
are expressed in different cell types (Braissant, 1996). The PPARs are involved in the 
control of gene expression by interacting with specific DNA response elements 
(PPAR response elements; PPREs) located upstream of PPAR target genes (Tugwood 
et al., 1992). The PPARs, which are normally localized in the cytoplasm, are activated 
by binding of PPs or fatty acids, which causes translocation of PPAR to the nucleus 
and induces conformational changes that enable the PPARs to bind to the PREs 
(Figure 5). The common examples of fatty acids that bind to the PPARs and induce 
signalling are lenoleic acid, oleic acid, arachidonic acid and prostaglandin J2 (Heuvel, 
1999, Huang et al., 2002, and Holness et al., 2002). The common examples of PPs 
used regularly are Wy14,643 and clofibric acid (Issemann and Green, 1990 and 
Dreyer et al., 1992). 
 
Several studies have shown that PPAR α and γ induce PDK4 gene expression 
(Holness et al., 2002; Huang et al., 2002; Sugden et al., 2001 and Wu et al., 2001). In 
these studies, the PPAR receptors were activated by Wy14,643, lenoleic acid, and 
oleic acid (Holness et al., 2002).  
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Figure 5. Signalling thorugh fatty acids (FAs) and peroxisome proliferators (PPs). 
Binding of PP or FA to the peroxisome proliferators-activated receptors (PPAR) leads 
to conformational change that result in the translocation of the complex to the 
nucleus. The complex then binds to the peroxisome proliferator response elements 
(PPRE) and activates the target gene. 
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PPARs are also able to regulate gene expression independently of binding to DNA via 
receptor-dependent trans-repression. This mechanism involves a physical interaction 
of PPARα with the nuclear factor kappa B (NFκB) (Planavila et al., 2005). NFκB is 
present in the cytoplasm as an inactive heterodimer consisting of p50 and p65 
subunits. However after activation the heterodimer translocates to the nucleus and 
interact with PPARβ/δ. This association prevents PPARβ/δ from binding to its 
response element and thereby inhibits its ability to induce gene transcription leading 
to a reduction in the expression of PDK4 (Planavila et al., 2005). 
 
1.2.2.3 Signalling pathway activated by Glucocorticoids 
 
Glucocorticoids have been shown to be involved in PDK4 gene regulation. This was 
demonstrated by the discovery of the glucocorticoids response elements (GRE) 
located within the promoter region of the PDK4 promoter (Kwon et al., 2004). This 
region has been shown to be utilised by other corticosteroids as well such as 
dexamethasone. Both glucocorticoids and dexamethasone induce PDK4 gene 
expression through the GRE (Kwon and Harris, 2004). Activation of the 
glucocorticoids receptor (GR) through binding by glucocorticoids translocates into the 
nucleus where it forms a homodimer and binds to the GRE thus induce PDK4 gene 
expression (Kwon et al., 2004). GR activation of target genes depends on cooperative 
interaction with p300/CBP to be able to activate its target genes (Van der Heide and 
Smidt, 2005). P300/CBP is believed to have multiple surfaces that enable cooperative 
interactions with other corticosteroids as well which includes dexamethasone and 
FOXO factors (Kwon et al., 2004).  
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The presence of p300/CBP in any complex may promote the rate of formation of a 
stable transcriptional initiation complex and thereby enhance the rate of PDK4 
transcription.  
 
The presence of the three IRSs near to the GRE may interfere with the interaction 
between p300/CBP complex and the general transcriptional machinery (Kwon and 
Harris, 2004). In the presence of insulin FOXO factors are inhibited from binding to 
the IRSs thereby decreasing the rate of formation of a stable initiation complex. This 
result in the suppression of the glucocorticoids response thus leads to inhibition of 
PDK4 gene expression (Kwon et al., 2004). 
 
1.3 Regulation of PDK4 by protein-protein interaction  
 
Protein-protein interactions are essential in cellular events such as protein and vesicle 
trafficking, cell cycle, apoptosis, gene expression, DNA repair, control of the 
cytoskeleton and targeted protein degradation (Pawson and Nash 2003). Protein-
protein interaction also plays a role in signal transduction. As part of our aim to 
understand the regulation of PDK4, we explored how PDK4 is regulated by protein-
protein interaction. Currently, the understanding of regulation of PDK4 by protein-
protein interaction is limited to what is known about its interaction with PDC (Popov 
et al., 1993). In this instance, the interaction of PDK4 with the lipoyl domain of PDC 
results in the activation of PDK4 (Bowker-Kinley et al., 1999).  
 
 
 
  15 
We wondered whether there are other proteins which affect the activity of PDK4 by 
binding PDK4. We therefore used bioinformatics tools to uncover possible interacting 
partners for PDK4 in order to further explore the role of protein-protein interactions in 
PDK4 activity. We identified death domain (DD) containing proteins such as nuclear 
factor kappa B (NFκB) subunit p100/p49 (referred to as p100), as potential interacting 
partners for PDK4. These proteins are known to be involved in apoptosis and inhibit 
NFκB by binding it and therefore retaining it in the cytoplasm (Ghosh and Karin, 
2002). 
 
1.4 The role of NFκB and p100 in apoptosis  
1.4.1 Signal transduction pathways involved in induction of apoptosis  
 
Apoptosis also known as programmed cell death is an important cellular process that 
is used by organisms to eliminate unwanted or damaged cells (Desaghner and 
Martinou, 2000; Kannan and Jain, 2000; Dlamini et al., 2004). Failure in proper 
regulation of apoptosis can lead to various genetic diseases such as neurodegenerative 
disorders, immune deficiency and cancer (Nur-E-Kamal et al., 2004). There are two 
major pathways that lead to apoptosis and are namely extrinsic (type I) and intrinsic 
(type II). These two pathways are induced by different factors (Bishopric et al., 2001 
and Dlamini et al., 2004).  
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Figure 6. The schematic diagram showing the two main apoptotic pathways. The type 
I (extrinsic) involves death receptors such as Fas and TNFR1. (a)-(k) Induction of 
apoptosis by binding of Fas and TNFR1 ligand to the receptors and activation of 
cascade leading to apoptosis. Type II (intrinsic) pathway involves the release of 
cytochrome c by the mitochondrion (Adapted from Bishopric et al., 2001). 
 
The type I pathway is mediated by external factors that binds to the transmembrane 
receptors containing death domain (Bishopric et al., 2001) for example Fas (also 
known APO-1/CD95) and (tumor necrosis factor-α receptor-1) TNFR1. Binding by 
Fas ligand and tumor necrosis factor-α (TNFα) induces aggregation of other factors at 
the receptor which leads to the cleavage and activation of caspase 8 from procaspaase 
which in turn activate caspase 3 (figure 6). Type II pathway is dependent on the 
release of cytochrome c by the mitochondrion (figure 6). Cytochrome c then forms a 
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complex with procaspase 9 and its cofactor apoptotic protease activating factor-1 
(APAF-1). Sufficient ATP is needed for caspase 9 to undergo conformational change 
which produces active apoptosome which further activates caspase 3 which results in 
apoptosis (Bishopric et al., 2001).  
 
1.4.2 NFkB and the death receptor pathway  
 
One of the two main signalling pathways, the death receptor pathway, is of interest as 
it involves DD containing proteins (Schlessinger and Ullrich, 1992). This pathway is 
induced by binding of DD containing ligands such as Fas and tumor necrosis factor α 
(TNFα) and these lead to the activation of the caspase cascade (Schlessinger & 
Ullrich, 1992). Studies have shown that binding of TNFα to TNFα receptor 1 (TNFR-
1) induces nuclear factor kappa B (NFκB) activation. NFκB is a DNA binding protein 
that is involved in the activation of genes encoding proteins involved in apoptosis 
(Kim et al., 2005). NFκB is a member of the Rel/NFκB protein family of transcription 
factors that regulate many cellular processes including apoptosis, immune and 
inflammatory responses, and cell growth (Liang et al., 2006, Anaranda and 
Prefontaine, 1994, Huang et al., 1997 and McKay and Cidlowski, 1999). These posses 
similar structural elements which include a highly conserved N-terminal Rel 
homology domain that contains a DNA binding sub-domain, a dimerization sub-
domain; and a nuclear localization signal as shown in figure 7 (Anaranda and 
Prefontaine, 1994 and Bours et al., 1990). The C-termini of these proteins separate the 
family into two classes. p65 (RelA), RelB, and c-Rel belong to class I which is 
characterized by the presence of a transactivating domain in the C-terminus which 
confers the ability to activate transcription (Blank et al., 1991 and Kunsch et al., 
1992).  
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Figure 7.  Schematic diagram depicting structural elements of the Rel/NFkB protein 
family members. 
 
Class 2 of NFκB transcription factors include p100 and p105 and are characterized by 
long C-termini which are composed of multiple copies of 30-33 amino acid ankyrin 
repeats figures 7 & 8 (Scheinman et al., and Binizzi et al., 2004). The ankyrin repeats 
are believed to be responsible for the cytoplasmic retention of the NFκB subunits and 
therefore inhibition of NFκB activity (Anuranda and Prefontaine, 1994 and Bours et 
al., 1990, Scheinman et al., 1993 and Bonizzi et al., 2004). Consistent with this role, 
the C-terminal domain of Class 2 NFκB transcription factors is structurally similar to 
proteins termed inhibitors of NFκB (IκB’s) that are known to interact with Class 1 
NFκB transcription factors, thus inhibiting their activity. The Class 2 NFκB 
transcription factors are activated through proteolytic cleavage which results in the 
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generation of p50 and p52 from the N-terminus, as well as IκB-γ from the C-terminus 
(figures 7 & 8, Grimm and Baeuerle, 1995 and Liou H-C, 2002).  p49, a protein that is 
highly related to p50 and functions in a similar manner to p50 is also derived from the 
p100 gene through alternative splicing (Schmid et al., 1991). Hence, p100 is also 
sometimes referred to as the p100/49. However, p49 has not been as extensively 
studied as its p50 relative.  
Proteolytic cleavage Alternative splicing of the  p100 gene
p100 or p105
+
IκB-γp50 or p52
p49
1 2 3 4 5 6 7
IκB-like C-terminal domain
with Ankyrin repeats
N-terminal Rel
Homology domain
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Dimerization sub-domain (also binds IκB-like domain)
Nuclear localization sequence (NLS)
DNA binding sub-domain
 
Figure 8. Schematic overview of the structure and generation of Class 2 NFκB 
subunits.  
 
The NFκB subunits can interact with one another to form a diversity of homo- or 
hetero-dimers, which enables NFκB transcription factors to regulate distinct, but 
overlapping sets of genes (Liou H-C, 2002, Grimm and Baeuerle, 1993 and McKay 
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and Cidlowski, 1999). The most abundant NFκB complex in most cells is the p50-p65 
hetero-dimer (Ganchi et al., 1993 and Duckett et al., 1993). This binding occurs via 
interaction between the dimerization sub-domains of the NFκB subunits, resulting in 
the formation of an active NFκB heterodimer (Duckett et al., 1993 and Huang et al., 
1997). 
 
1.4.3 Signal transduction through NFκB 
 
In the classical signalling pathway, the NFκB dimer is normally found in an inactive 
form bound to its inhibitory proteins IκBs (Ghosh et al., 1998 and Gosh and Budde, 
2000). Activation of signal transduction by external stimuli result in activation of the 
IκB kinases (IKKs) on two conserved serine residues (Bonnet et al., 2006), which 
then results in phosphorylation of the IκBs thus leading to the release of dimeric 
NFκB and its translocation to the nucleus, where it activates gene transcription 
(Orange and Geha, 2003; Vestergaard et al., 2005 and Gosh and Karin, 2002) shown 
below on figure 9. The phosphorylation of IκB also results in its ubiquitinylation and 
proteosomal degradation (Liang et al., 2006, Bonizzi et al., 2004 and Iwai et al., 
2005). Regulation of the interaction between IκB and NFκB complexes is central to 
regulation of NFκB activity.   
 
In the non-classical pathway, p100 or p105 is complexed with any of the Class 1 (Rel) 
subunits (e.g. p65).  Phosphorylation of the C-terminal IκB-like domain by IKK 
results in the ubiquitinylation and degradation of the C-terminal IκB-like domain, 
which generates an active p50/p52-p65 NFκB dimer (Duckett et al., 1993, Ray and 
Prefontaine, 1994 and Blank et al., 1991).   
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Figure 9. The schematic diagram indicating the role of IκBs in NFκB signalling 
pathway and apoptosis. (A) The classical and (B) The non-classical NFκB signalling 
pathways. CM stands for cell membrane, R stands for receptor and N stands for 
nucleus. RH stands for Rel homology domain and P stands for the phosphate group. 
 
1.5 NFκB and PDK4: Roles in apoptosis and Type II diabetes 
 
 
The role of NFκB in apoptosis has been extensively demonstrated in several studies 
(Lui et al., 1996, Karin and Lin, 2002, Ghosh and Karin, 2002 and Kim et al., 2005) 
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where they showed that inhibition of NFκB protects cells from apoptosis and that 
overexpression of NFκB results in induction of apoptosis. Another interesting 
function of NFκB was demonstrated by Chen (2005), where he indicated a role for 
NFκB in insulin resistance and diabetes. Since the role of PDK4 in insulin resistance 
and diabetes has been extensively demonstrated (Huang et al., 2002 and Majer et al., 
1998), and the bioinformatics analysis that we performed suggested possible 
interaction between PDK4 and IκB-like p100, we became interested in exploring the 
relationship between PDK4 and apoptosis. 
 
In addition to the work by Chen et al (2005), several studies have also suggested a 
link between apoptosis and diabetes. For example, studies by Mandrup-Polsen et al 
(2003) demonstrated that apoptosis is important in pancreatic β cell failure that 
accompanies T2D. Further, glycogen synthase kinase-3 (GSK3) an enzyme that has 
been shown to be important in diabetes was reported to induce apoptosis when over 
expressed in mammalian cells (Pap and Cooper, 1998 and Cross et al., 1995). In 
addition, insulin, a hormone that protects against diabetes and regulates expression of 
PDK4, is known to prevent apoptosis by activating the phosphatidylinositol kinase 3 
pathway (Whitehead et al., 2000; Baumann and Saltiel, 2001). All these factors led us 
to the hypothesis that overexpression of PDK4 may play a role in induction of 
apoptosis. Since our bioinformatics analysis suggested an interaction between PDK4 
and IκB-like p100, we postulated that PDK4 may compete with other NFκB subunits 
for the binding site in IκB. This may enable the formation of functional NFκB dimers 
that are able to translocate to the nucleus and activate pro-apoptotic genes.  
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1.6 Objectives of the study 
 
Pyruvate dehydrogenase kinase 4 (PDK4) has emerged as an interesting candidate in 
diabetes therapy. Due to high increase in diabetes complications and death numbers 
we aim at understanding PDK4 regulation by other proteins. The study will assist in 
determining whether targeting the interaction of PDK4 with other proteins can be 
used in the treatment of diabetes or other physiological complications that involve 
PDK4.  
 
Our main objective was to study regulation of PDK4 through protein-protein 
interactions. This involved the use of bioinformatics tools to reveal proteins that 
potentially interact with PDK4 through protein-protein interactions. Bioinformatics 
was also used to identify the protein binding consensus sequence of the identified 
proteins in human PDK4 (hPDK4) protein sequence. Furthermore, the potential 
protein binding region on hPDK4 structure was also identified. Studies were also 
performed in mammalian cell culture to begin to uncover the relationship between 
PDK4 and its identified interacting partners. 
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CHAPTER 2 
 
2 Materials and Methods 
 
To begin our study we sought to use bioinformatics tools to determine if there are any 
proteins that may interact with PDK4. Since we are interested in the regulation of 
PDK4 by other proteins especially that may interact with it through protein-protein 
interaction, bioinformatics analysis was applied. 
 
2.1 Bioinformatics analysis 
 
Bioinformatics tools were used to analyse potential protein-protein interactions 
between PDK4 and other proteins. 
 
2.1.1 Analysis of protein-protein interaction  
 
The interweaver database (http://interweaver.i2r.a-star.edu.sg/) was used to identify 
proteins that would potentially interact with hPDK4 (Zhang and Ng, 2004). This tool 
uses a domain-based approach to search for domain-domain interactions (Ng et al., 
2003) in the database by using computationally derived domain fusion events 
(Marcotte et al., 1999). These allow identification of proteins with domains that 
putatively interact with a domain in the source protein in this case hPDK4. The 
national centre for biotechnology information (NCBI) database 
(http://www.ncbi.nlm.nih.gov/) was used to retrieve the hPDK4 amino acid sequence 
and convert it to a FASTA format. This was then used in the interweaver instrument 
to search proteins with domains that can potentially interact with hPDK4. 
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2.1.2 Consensus sequence identification 
 
The primary sequence of hPDK4 was aligned with the amino acid sequences of NFκB 
subunits that are known to be important in dimerization. For this purpose, a sequence 
alignment program (ClastalW) was used. This program was also used to explore 
whether these amino acids are also conserved in the other PDK isoforms from 
different species. 
 
2.1.3 Structural localization of the hypothetical protein binding region in 
hPDK4 
2.1.3.1 Modelling of hPDK4 
 
The structure of hPDK4 was modelled based on the coordinates of the published 
structure of rat PDK2 (1JM6 Pdb code, Steussy et al., 2001).  Briefly, the primary 
protein sequence of hPDK4 was aligned with that of rat PDK2 using Clustal W, 
version 1.83 (Pearson, 1990). A molecular graphics program (Swiss Pdb Viewer, 
Guex, N, 1996) was then used to build the hPDK4 structure. The quality of the 
modelled structure was verified using the WHATIF program (Vriend, 1990) and 
Rachamandran Plot. 
 
 
2.1.3.2 Localization of the hypothetical protein binding region in hPDK4 
structure 
 
Swiss-Pdb Viewer was used to visualize the 3-dimentional (3D) structure of the 
modelled hPDK4. The positions of the amino acids that are conserved between 
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hPDK4 and NFκB subunits were located and visualized within the 3D structure of 
hPDK4. 
 
 
2.2 Cellular and Molecular Analysis 
 
To further understand the relationship between PDK4 and apoptosis at the molecular 
level cell culture studies were performed. Cell culturing has become a very useful and 
powerful technique in biological research. These studies involved the usage of HeLa, 
a cervical carcinoma cell line and HepG2, a hepatocellular carcinoma cell lines for 
apoptotic assays, RNA extraction and RT-PCR analysis.  The primary role for using 
these two cell lines is that they are known to express PDK4 protein.   
 
2.2.1 Culturing of cells 
 
HeLa and HepG2 cells were purchased from Highveld Biologicals (PTY) LTD (South 
Africa). These were grown in T-75 flasks or 100-mm dishes at a density of 0.5 X 104 
cells/cm2 in Dulbecco’s Modification of Eagle’s Medium (DMEM) containing 10% 
fetal bovine serum (FBS), 100 units/ml of penicillin, and 100 units/ml of 
streptomycin.  
The cells were grown by incubation at 37˚C in a 5% CO 2 incubator (Sanyo, MCO-
15AC, Japan). The cells were then grown in serum-free medium containing 0.25% 
BSA for 24 hours, and then treated with C2-Ceramide (Sigma Aldrich, USA), or 
Linoleic acid that is conjugated to BSA at a concentration of 0.02g Linoleic acid /1g 
BSA (Highveld Biologicals, Gauteng), or TNFα (Sigma Aldrich, USA) at indicated 
concentrations and time periods. 
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2.2.2 Cell Viability Assay 
 
Cell viability assays are mainly performed to accurately estimate the number of viable 
cells against the dead cells in mammalian tissue cultures. Trypan blue dye exclusion is 
the most common utilised test for cell viability. The basic principle of this test is that 
the dye is taken up by the cells that have lost their membrane permeability barrier and 
thus are considered nonviable.     
 
For this study, cell viability was determined by trypan blue exclusion method (Kim 
and Kim, (2003). Cells were detached with trypsin/EDTA and diluted 1:1 with 
medium supplemented with 10% fetal bovine serum. The cell suspension was mixed 
with an equal volume of 0.4% trypan blue solution (Sigma Aldrich, USA). The cells 
were then applied to a hematocytometer and counted under a phase-contrast inverted 
Neubauer (Carl Zeiss, Germany). The unstained cells were considered to be viable.  
 
 
2.2.3 DNA laddering assay 
 
Detection of apoptosis in cells after induction of apoptosis involves different 
techniques depending on the experiment. DNA laddering assay was chosen for our 
study for the detection of apoptosis. This technique involves extraction of DNA from 
the cells. The DNA is then loaded on the agarose gel and visible DNA laddering 
occurs. The ladder is a result of the fact that apoptosis is associated with the 
fragmentation of chromosomal DNA into multiples of the 180 bp nucleosomal units 
(Gong et al., 1994). 
 
 
  28 
DNA laddering assays were performed using a Suicide Track DNA Laddering kit that 
was purchased from Calbiochem (USA). Briefly, cells were trypsinized and washed 
with PBS. The cell suspension of 0.5 x 106 was then transferred to a microcentrifuge 
tube and spun down. DNA was extracted from the resuspended pellet according to 
manufacturer’s instructions. DNA was quantified by measuring absorbance at 260 
nm. DNA laddering was visualized by resolving the DNA in an agarose gel which 
was stained in ethidium Bromide. 
 
2.2.4 RNA Extraction 
 
RNA extraction is the technique whereby total RNA is extracted from the tissues or 
cell line samples. The most easiest and common RNA extraction method used 
involves the use of TRIzol TM LS REAGENT. This method utilizes the four phases 
which includes disruption, homogenisation, phase separation and RNA precipitation. 
The cell wall and membrane of cells are disrupted followed by homogenisation and 
RNA precipitation.  
 
RNA was isolated (detailed method in Appendix 1) from HeLa and HepG2 cells using 
the TRIzolTM LS REAGENT according to manufacturer’s instructions (Sigma 
Aldrich, USA). RNA was quantified by measuring absorbance at 260 nm and also 
using a Nanodrop (Nanodrop technologies, USA).  The accuracy of quantification and 
the integrity of the RNA were confirmed by agarose gel electrophoreses. 
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2.2.5 Real Time Polymerase Chain Reaction (RT-PCR) 
 
Real-time PCR has become a very powerful technique for evaluating gene expression 
at the mRNA level. The evolution of PCR to the existence of Real-time PCR allows 
science to be used to compare gene expression under different condition e.g. early 
development, late development, normal cells and cancerous cells, in cells under 
apoptotic stimuli and in the absence of.  
 
The RT-PCR system is based on the fluorescence reporter. RT-PCR monitors the 
fluorescence emitted during the reaction as an indicator of amplicon production 
during each PCR cycle (i.e. Real Time) as opposed to the end point detection. This 
signal increases in direct proportion to the amount of PCR product formed after every 
cycle. The cycle at which this occurs is called the threshold cycle (Ct) which is 
defined as the cycle at which the fluorescence emission exceeds the fixed threshold. 
SYBR Green is one of the fluorescence reporter used in Real Time PCR. Its chemistry 
provides the simplest format for detecting and quantitating PCR products in real time 
reactions. This dye binds the minor grooves of a double stranded DNA. When SYBR 
Green dye binds to a double stranded DNA, the intensity of the fluorescence emission 
increases. As more double stranded amplicons are produced, SYBR Green dye signal 
will increase. Thus, as a PCR product accumulates, the fluorescence increases. 
 
The RT –PCR reaction was performed using iScript One Step RT-PCR kit (Bio-Rad, 
USA) according to the manufacturer’s instructions. A final reaction containing 2X 
SYBR Green RT-PCR reaction mix, 10 µM of the both the forward and reverse 
primers and 100ng mRNA along with the enzyme was used. The reaction protocol 
was as follows: cDNA synthesis: 50˚C for 10 min, enzyme inactivation:  95˚C for 5 
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min and followed by PCR cycle: 94˚ C for 30 sec, 58˚ for 30sec, 72˚C for 1 min 30sec, 
followed by a plate read and cycle repeat of PCR for 29 cycle and ended with 72˚ C 
for 10 min. Melting curve analysis was as follows: 95˚ C for 1 min and 55˚C for 1 min 
with a temperature increase of 0.5˚ C for every 10 sec.  The results were visualized on 
1% agarose gel with ethidium bromide and analysed using Mini Opticon Real Time 
PCR system (Bio-Rad MJ Personal Thermal Cycler). 
 
2.2.6 Polymerase Chain Reaction (PCR) 
 
Polymerase chain reaction (PCR) is a three step technique that allow for amplification 
of minute DNA quantity into a significant quantity of the fragment of interest through 
repetitive cycle of DNA synthesis. The gene of interest is amplified using primers that 
are complementary to the sequence of interest. The three steps include denaturation, 
annealing and elongations. Denaturation step involves the denaturation of the DNA 
double strand by high temperatures. Annealing involves annealing of the forward and 
reverse primers to the template DNA. The last step extension require molecules such 
as Taq polymerase, MgCl2, dNTPs and PCR buffer to synthesize the new strand of 
DNA. DNA polymerase is used to synthesise a double stranded DNA by 
complementary base pairing with DNA template.  
 
The PDK4 gene was amplified from the cDNA using specific primers for the PDK4 
gene. These specific primers for the PDK4 gene were designed using the DNA man 
program and sent to Inqaba Biotech (Pretoria, South Africa) for synthesis, forward 
full length primer (FF) 5’- GATACTCGAGCGATGAAGGCGGCCC -3’; forward 
short length primer (FS) 5’- CGGTCTCGAGAGAAAATGCATGTGAAAG -3’ and 
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reverse primer 5’ – TTCCCGGGGGTAAAGGCGGCCCCG -3’. The 25 µl PCR 
reaction mixture was prepared as shown in a table below.  
 
Table 1. PCR reaction mixture  
Reagent Final Concentration µl used 
10X PCR Buffer 1X 2.5 
MgCl2 (25 mM) 1.5 mM 1.5 
dNTPs (2.5 mM each) 200 µM of each 2 
Forward primer (10 µM) 10 µM 1 
Reverse primer (10 µM) 10 µM 1 
Template DNA 100 ng 3 
Taq polymerase (5 U/µl) 0.5 U 0.1 
ddH2O  13.9 
Total volume  25 
 
The samples were prepared in the PCR tubes and the lids closed very tightly before 
being subjected to the Mastercycler PCR machine (Eppendorf, Bio-Rad). The first 
step of the PCR is run once and the following three cycles, denaturation, annealing 
and extension are repeated 30 times and followed by the final extension step. The 
PCR conditions are shown below.  
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Table 2. PCR conditions 
 
 
 
 
 
 
 
The products were either stored at 4˚ C for further use or run on 1% electrophoresis to 
determine the correct molecular size. 
 
2.3 Cloning of PCR products in pGEM-T-Easy Vector 
 
Cloning is the technique whereby the DNA fragment of interest is ligated to a plasmid 
DNA vector which has the capacity to self replicate. This allows the fragment of 
interest to be replicated together with the vector thus resulting in many copies of the 
DNA of interest. pGEM-T-Easy vector is normally used for the purpose of cloning. 
This vector allows the cloning of PCR products without purifying it. LigaFast cloning 
system from Promega was used to clone PCR products containing the gene of interest 
PDK4 in pGEM-T-Easy vector. The cloning was performed to make a clone that will 
be used to plot the Real Time PCR standard curve. The detailed schematic of pGEM-
T-Easy vector is shown in Appendix 3. 
The cloning process involves ligation and transformation steps discussed below. 
 
 
Steps Temperature and time 
Denaturation 94˚C for 2 minutes 
Denaturation 94˚C for 30 seconds 
Annealing 58˚C for 30 seconds 
Extension 72˚C for 1 minute 30 seconds 
Elongation 72˚C for 10 minutes 
30 cycles 
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2.3.1 DNA ligations 
 
DNA ligation technique involves the construction of  recombinant DNA molecules 
following the ligation between the vector  and DNA fragment  of interest using DNA 
ligase usually T4 DNA ligase. 
 
The PCR products were cloned into the pGEM-T-Easy vector using the T ovehangs 
on it and the A overhangs of the inserts added during the PCR. T4 DNA ligase from 
fermentas was used for the ligation reactions. 3 µl of PCR product was mixed with 1 
µl of 10X ligation buffer, 1 µl of 10 ng of pGEM-T-Easy vector, 1 µl of T4 DNA 
ligase and 4 µl of sterile distilled water to a final volume of 10 µl. The mixture was 
prepared in an eppendorf tube, tapped to mix and briefly microfuged. The ligations 
were incubated at 22˚C for one hour. 
  
2.3.2 Transformations 
 
Transformation is the technique that involves genetic alteration of the cells resulting 
from the uptake and expression of foreign plasmid DNA. This technique allows for 
the selection and propagation of the selected plasmid DNA. Competent bacterial cells 
are used to take up the plasmid DNA followed by positive selection by growth on 
medium containing an appropriate antibiotic corresponding to the resistant genes in 
the plasmid DNA.  
The controls used in this technique included the negative control where the reaction 
mixture is without the clone and positive controls without PCR product or the vector. 
Escherichia coli JM109 was grown overnight in 5 ml Luria broth containing 100 
µg/ml ampicillin at 37˚C. The culture was then inoculated into a 100 ml Psi broth also 
containing ampicillin and grown with vigorous aeration at 37˚C until it reached an 
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O.D550 of between 0.4-0.6. The flask was then transferred to ice and incubated for 15 
minutes. The cells were centrifuged at 5 000 rpm for 5 minutes in a Sorvall SS-34 
rotor. The supernatant was discarded and 40 ml of TfbI buffer which is 0.4 volume of 
the original volume of Psi broth. The pellet was gently resuspended and incubated in 
ice for 15 minutes. The mixture was again centrifuged at 5 000 rpm for 5 minutes in a 
Sorvall SS-34 rotor. The supernatant again was discarded and 4 ml of TfbII buffer 
which is 0.04 volume of the original volume of Psi broth was added. The pellet was 
resuspended in TfbII buffer and incubated in ice for 15 minutes. The competent cells 
were then aliquote into amounts of 100 µl per eppendorf tubes and some stored at -
70˚C and some used immediately. 10 µl of the prepared ligations was added to a 100 
µl of competent cells. This was incubated for 20-30 minutes on ice to allow diffusion. 
The cells were immediately heat shocked for 90 seconds at 42˚C. They were then 
incubated for 5 minutes on ice. 500 µl of LB was added to the cells and they were 
incubated at 37˚C for one hour to allow phenotypic expression. 100 µl of the cells was 
then plated on ampicillin containing agar plates which were incubated at 37˚C 
overnight. 
 
2.3.3 Plasmid DNA extraction  
 
Plasmid DNA extraction method which is also known as the alkaline lysis is the 
technique that involves the extraction of the plasmid DNA from bacterial cells such as 
Escherichia coli by alkaline solutions.  
 
In order to get high quality plasmid DNA for further experiments such as restriction 
digestion plasmid DNA was extracted using Lysozyme boiling method described 
below. 
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Few transformants both white and blue were isolated from the plate and inoculated in 
5 ml of LB containing ampicillin and grown at 37˚C overnight. The cultures were then 
centrifuged at a maximum speed of 13 000 rpm for 2 minutes. The supernatant was 
discarded and the pellet was resuspended in 400 µl of STET buffer. 10 µl of 10 mg/ml 
lysozyme was added and the cells incubated for 20 minutes at 37˚C. The mixture was 
incubated in boiling water for 60 seconds and immediately put in ice for 10 minutes. 
These were then centrifuged at 13 000 rpm for 15 minutes and the supernatant was 
transferred to new eppendorf tubes. 400 µl of cold isopropanol was added and the 
tubes mixed several times by inversion.  The tubes were spun at maximum speed for 
10 minutes. The supernatant was carefully sucked out using the pipette and the pellet 
was washed in 1 ml of cold 70% ethanol. The pellets were centrifuged at maximum 
speed for 5 minutes and the supernatant carefully removed as much as possible. The 
pellets were then dried in a vacuum dryer for 15 minutes.  They were then 
resuspended in 50 µl of 5 mM Tris-HCl buffer (pH 8.5) containing RNAse. 
 
2.3.4 Plasmid DNA digestion 
 
Restriction digestion is the method used to determine the presence of the insert by 
determining the size of the insert. Restriction endonucleases are normally used in the 
method above to digest the clones. These enzymes have the ability to recognise and 
bind to the target specific DNA sequence.    These target DNA sequences are specific 
for each restriction enzyme and therefore the cleaved sequence will generate different 
cohesive ends corresponding to each restriction enzyme. These ends are very 
important in the ligation process as they allow binding to the vector due to 
compatibility with the ends on the vector resulting from digestion with the same 
enzyme. 
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Restriction analysis of the plasmid DNA was carried out using the three 
endonucleases from Fermentas. Xho I was used to linearize the clones whereas EcoRI 
was used to release the insert. To confirm whether our inserts are the right sizes Xho I 
and Not I were used. DNA from each clone was mixed with appropriate restriction 
buffers as specified by the manufacturer.  
 
The restriction enzymes were added and sterile water used to make up to a final 
volume. The mixture was tapped and microfuged before incubating overnight at 
appropriate temperatures. Incubation temperatures were specific to each endonuclease 
as specified by the manufacturer. The restriction digests are shown on tables below. 
 
Table 3. Restriction digestion for EcoRI and Xho I 
          EcoRI        Xho I 
Buffer 10X 1.0 µl 1.0 µl 
pGEM-T-Easy clone 3.0 µl 3.0 µl 
Restriction enzyme 1.0 µl 1.0 µl 
Sterile distilled water 5.0 µl 5.0 µl 
Total volume 10 µl 10 µl 
  
These digestions were performed separately for each restriction endonuclease. 
 
 
 
 
 
  37 
Table 4. Double digestion for Xho I and Not I 
 Xho I Not I 
Buffer 10X 1.0 µl - 
pGEM-T-Easy clone 3.0 µl - 
Restriction enzyme 1.0 µl 1.0 µl 
Sterile distilled water 4.0 µl - 
Total volume 10 µl - 
 
The double digestions were performed at the same time with the buffer that is suitable 
for both restriction endonucleases.  
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APPENDIX 1 
 
1.0 Methods 
1.1 Cell Lines 
 
HeLa and HepG2 cells were purchased from Highveld Biologicals (PTY) LTD (South 
Africa). The two cell lines were cultured according to the manufacturer’s instructions. 
 
1.2 Culturing of cells 
 
 
1. The cells were allowed to grow until they formed a monolayer in the flask and 
were about 85-95% confluence.  
2. Confluent cells were trypsinized using trypsin/EDTA from Highveld 
Biologicals.  
3. The cells are then washed twice with 5 ml phosphate buffered saline (PBS).  
4. One ml of trypsin was added to the flask and incubated at 37˚C for less than 5 
minutes to detach the cells from the surface of the flask.  
5. Then 5 – 10 ml of medium was added and the mixture was transferred to 15 
ml centrifuge tubes and centrifuged at 3000 rpm for 5 minutes. (This step is 
very important as it removes the trypsin).  
6. After centrifugation, the supernatant containing trypsin was sucked out.  
7. Then 10 ml of 10% FBS medium was added and the pellet was gently 
resuspended with a pipette and the cells were split equally into flasks and 
stocks made for future use.  
8. Stocks were made by adding 1 ml of 10% freezing media to the pellet and then 
resuspended very gently.  
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9. The mixture was then transferred to the cryovial tubes which are suitable for 
extreme cold temperature.  
10. The tubes were sealed tight and put in ice for 30 minutes before being put at -
20˚C for overnight.  
11. The next day the tubes were transferred to a -70˚C freezer for storage until 
further use.  
 
1.3 Induction of apoptosis 
 
1. Cells were seeded in 100 mm x 20 mm Petri dishes at a density of 1 – 5 x 106 
cells/ml.  
2. They were cultured at the above mentioned conditions for 24 hours before 
treating them with the three known inducers of apoptosis ceramide, TNFα and 
Linoleic acid.  
3. Washed twice with PBS and treated with two differing concentration of each 
inducer of apoptosis at three different time intervals.  
4. The concentrations were as follows: 20 µM and 40 µM of ceramide, 25 ng/ml 
and 50 ng/ml of TNFα and 300 µM and 1 mM of Linoleic acid all for 24, 48 
and 72 hours.  
5. The control was included for each time interval where cells were treated with 
serum free media.  
6. After each treatment the cells were harvested by trypsinization and centrifuged 
at 3000 rpm for 5 minutes before performing cell viability assay. 
 
1.4 DNA extraction 
 
1. Cells were trypsinized briefly and washed with PBS.  
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2. The cell suspension of 0.5 x 106 was then transferred to a microcentrifuge tube 
and spun down.  
3. The pellet was then resuspended gently in 55 µl of solution 1.  
4. After adding 20 µl of solution 2 the sample was then incubated at 37˚C for one 
hour. 25 µl of solution 3 was added to the mixture, mixed gently and then the 
sample was incubated for another hour at 50˚C.  
5. The sample was then resuspended in 500 µl of resuspension buffer and mixed.  
6. To precipitate DNA 2 µl of pellet paint and 60 µl of 3M sodium acetate was 
added to the sample.  
7. Also 662 µl of isopropanol was added and the sample mixed by inversion 
several times and allowed to stand at the room temperature for 2 minutes.  
8. The sample was then centrifuged at 13 000 rpm for 5 minutes.  
9. A pink pellet was visible in the bottom of the tube indicating the presence of 
the DNA.  
10. The supernatant was then removed with a pipet tip and the pellet rinsed with 
500 µl of 70% ethanol.  
11. The sample was again centrifuged at 13 000 rpm for 5 minutes.  
12. The supernatant was removed and pellet rinsed with 500 µl of 100% ethanol.  
13. The sample was again centrifuged at 13 000 rpm for 5 minutes and the 
supernatant removed with a pipet tip.  
14. The DNA pellet was allowed to air dry on the benchtop for a few minutes at 
room temperature.  
15. Then the pellet was then resuspended in 50 µl of resuspension buffer and 
stored at -20˚C for further use. 
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1.5 RNA extraction 
 
1. The cells were seeded at a density of 0.5 x 106 on 100mm Petri dishes for two 
days.  
2. Washed with PBS and treated with serum free medium for 24 hours.  
3. Then treated with TNFα (50ng/ml), C2-Ceramide (50μM) and Linoleic acid 
(300μM) for 24, 48 and 72 hours.  
4. The cells were then harvested by trypsinization and then media was added to 
neutralise it.  
5. Centrifuged at 3000 rpm for 5 minutes before resuspending them in 1 ml of 
TRIzolTM LS REAGENT.  
6. The sample was allowed to stand for 5 minutes at room temperature.  
7. Then 0.2 ml of chloroform per 1 ml TRIzolTM LS REAGENT was added and 
the tube shaken vigorously for 15 seconds and allowed to stand for 2-15 
minutes at room temperature.  
8. The sample was then centrifuged at 10 000 rpm for 15 minutes at 4°C and the 
mixture separated into three phases: a colorless upper aqueous phase (RNA), 
an interphase (DNA) and a red organic phase (proteins).  
9. The colorless aqueous phase was transferred into a fresh eppendorf tube and 
0.5 ml isopropanol per ml of TRIzolTM LS REAGENT was added and mixed.  
10. The sample was then allowed to stand for 5-10 minutes at room temperature.  
11. The samples were then centrifuged at 10000 rpm for 10 minutes at 4°C to 
collect the RNA pellet at the bottom of the tube.  
12. The supernatant is then removed and the pellet is washed with 1 ml of 75% 
ethanol per 1 ml TRIzolTM LS REAGENT.  
13. The sample is then votexed and centrifuged at 8 500 rpm for 5 minutes at 4°C.  
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14. The pellet was then briefly air-dried for 5-10 minutes (do not use speed vac).  
15. Then 100μl of RNAse free water was added and the sample warmed at 55°C 
for 10-15 minutes.  
16. The sample was then stored at -20°C for further use. 
 
1.6 Agarose gel 
 
Agarose gel electrophoresis is a method used for analyzing nucleic acids in terms of 
their sizes and conformations. This technique separates DNA fragments by migration 
on the gel based on the size and shape of the molecule, charge of the current and the 
resistance of the medium. Since the DNA molecule is negatively charged, when 
loaded on the gel it is normally loaded at the cathode end of the gel and moves 
towards the anode. 
 
The samples (DNA fragments) were quantified and visualized on 1% agarose gel. The 
visualization of samples was achieved by staining with ethidium bromide (EtBr) 
which intercalates between the bases of the DNA. EtBr illuminates the gel when 
viewed under the UV light transluminator.  
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1.6.1 Preparation of agarose gel 
 
1. The gel was prepared by melting 1 gram of agarose in 100 ml of 1XTBE 
buffer using the microwave oven.  
2. It was allowed to stand until it reaches 50˚C temperature before 6 µl of EtBr 
was added and mixed evenly.  
3. The gel was then poured into the gel tray and allowed to polymerize for 20 
minutes after fitting the comb in the right place.  
4. The comb was then removed and the gel subjected to an electrophoresis tank 
containing 1X TBE buffer enough to cover the gel.  
5. Then 5-10 µl DNA samples were mixed with 2µl bromophenol blue dye and 
loaded onto the wells using a pipet.  
6. Bromophenol blue is a loading dye that acts as a marker to indicate when to 
stop the electrophoresis.  
7. A 1000 base pair molecular weight marker used was 1000 base pairs from 
Fermantas, South Africa.  
8. The gel was subjected to electrophoresis at 100 volts using Consort E502 
power system.  
9. After the solvent front from the marker reached the bottom of the gel, the gels 
were photographed with ChemiDoc XRS system (Bio-Rad, Italy).  
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APPENDIX 2  
 
 
2.1. Tissue Culture media preparations 
 
10% FBS media (100ml) 
10 ml FBS 
1 ml streptomycin/penicillin (100 units/ml of each) 
89 ml serum (DMEM) 
Filter sterilize 
 
Freezing media (10 ml) 
9 ml (10 or 20% FBS media) 
1 ml autoclaved glycerol (100%)  
 
0.4% trypan blue solution (100 ml) 
0.4g of trypan blue powder 
Fill to 100 ml with sterile water 
 
2.2 Media Preparations 
 
Luria Broth (LB) 
1 % tryptone 
0.5 % yeast extract 
0.5 % NaCl 
 
Luria Agar (LA) 
1 % tryptone 
0.5 % yeast extract 
0.5 % NaCl 
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1.5 % technical agar 
 
Psi Broth 
1 % tryptone 
0.5 % yeast extract 
0.5 % NaCl 
0.5 g MgSO4 
 
20% glucose solution (100 ml) 
 
20g glucose 
 
Fill to 100 ml sterile water 
 
Autoclave 
 
 
2.3 Plasmid Preparation solutions 
 
STET buffer 
8 % sucrose 
0.1 % Triton X-100 
50 mM Tris-HCl (pH 8.0) 
50 mM EDTA 
 
TE buffer 
10 mM Tris-HCl (pH 8.0) 
10 mM EDTA (pH 8.0) 
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2.4 Agarose gel electrophoresis solutions 
 
5X TBE 
13.5g Tris 
6.85g boric acid 
5 ml 0.5 M EDTA (pH 8.0) 
250 ml distilled water 
Autoclaved 
 
0.5 % TBE 
50 ml 5X TBE 
450 ml distilled water 
 
1 % Agarose 
1 g agarose 
100 ml 5X TBE  
Autoclave 
 
Tracking dye 
30 % glycerol in TE 
0.025 % bromophenol blue 
 
Ethidium bromide 
10 mg/ml in sterile distilled water 
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2.5 Bacterial transformation solutions 
 
TfbI 
30 mM KOAc 
100 mM RbCl 
10 mM CaCl2 
50 mM MnCl2 
15 % glycerol 
pH 5.8 with acetic acid 
 
 
TfbII 
10 mM MOPS buffer 
10 mM RbCl 
75 mM CaCl2 
15 % glycerol 
pH 5.8 with acetic acid 
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APPENDIX 3 
 
3.1. Vectors 
 
 
 
Figure 10. pGEM-T Easy vector map 
The pGEM-T Easy vector is made up of 3018 bp with the T7 and SP6 RNA 
polymerase initiation sites at position 1 and 141 respectively. The T7 RNA 
polymerase promoter region occurs between 3002 and 3006 whereas SP6 promoter 
region occurs at positions 136 and 158. 
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APPENDIX 4 
 
4.1 List of reagents and companies 
 
Acetic acid   Merck (Germany) 
Agar    Merck (Germany) 
Agarose   Merck (Germany) 
Boric acid   Merck (Germany) 
Bromophenol Blue  Merck (Germany) 
BSA    Highveld Biologicals (SA) 
C2-Ceramide   Sigma Aldrich (USA) 
CaCl2   Merck (Germany 
Chloroform Merck (Germany) 
DMEM   Highveld Biologicals (SA) 
EDTA    Sigma Aldrich (USA) 
Ethanol Merck (Germany) 
FBS    Highveld Biologicals (SA) 
Glycerol   Sigma Aldrich (USA) 
HCl    Merck (Germany) 
Isopropanol   Merck (Germany) 
KOAc Merck (Germany) 
LA    Sigma Aldrich (USA) 
LB    Sigma Aldrich (USA) 
Linoleic acid   Sigma Aldrich (USA) 
Lysozyme   Sigma Aldrich (USA) 
MgSO4   Sigma Aldrich (USA) 
MnCl2        Merck (Germany) 
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MOPS    Merck (Germany) 
NaCl    Merck (Germany) 
PBS    Highveld Biologicals (SA) 
Penicillin   Sigma Aldrich (USA) 
RbCl    Merck (Germany)  
Streptomycin   Sigma Aldrich (USA) 
Sucrose   Sigma Aldrich (USA) 
TBE    Inqaba Biotechnologies (SA) 
TNFα    Sigma Aldrich (USA) 
TRI Reagent   Sigma Aldrich (USA) 
Tris    Sigma Aldrich (USA) 
Triton-X-100   Sigma Aldrich (USA) 
Trypan blue dye  Sigma Aldrich (USA) 
Trypsin   Sigma Aldrich (USA) 
Tryptone   Merck (Germany) 
Yeast extract   Merck (Germany) 
 
4.2 Kits 
 
iScript One Step RT-PCR kit   Bio-Rad (USA) 
Suicide Track DNA Laddering kit  Calbiochem (USA) 
PCR kit     Promega 
pGEM-T-Easy kit    Promega    
Gel Purification kit    Promega 
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CHAPTER 3 
 
 
3 Results 
 
 
Since we hypothesized that PDK4 is regulated through protein-protein interactions, 
bioinformatics tools were used to determine if there are any proteins that may interact 
with PDK4 through protein-protein interaction. The results of these studies are shown 
below. 
 
3.1 Bioinformatics analysis of proteins that potentially interact with PDK4 
 
3.1.1 Identification of proteins that potentially interact with PDK4 
 
Bioinformatics tools were used to analyse potential protein-protein interaction 
between PDK4 and other proteins. To this end, the interweaver database 
(http://interweaver.i2r.a-star.edu.sg/) was used to identify proteins that would 
potentially interact with hPDK4 (as described in materials and methods). This 
exercise resulted in identification of a number of domains that have the potential to 
interact with PDK4. The list of these domains is shown on Table 5.  
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Table 5. Domains that are predicted to interact with hPDK4  
                                     Domains that potentially interact with hPDK4 
ATPase family 
associated with various 
cellular activities 
(AAA) 
Kinesin motor domain Helix-hairpin-helix motif 
Helix-loop-helix DNA-
binding domain 
Ubiquitin family Zinc finger C-x8-C-x5-C-x3-H type 
(and similar) 
Hsp70 protein DEAD/DEAH box 
helicase 
Proliferating cell nuclear antigen, N-
terminal domain 
Kunitz/Bovine 
pancreatic trypsin 
inhibitor domain 
Helicase conserved C-
terminal domain 
HhH-GPD superfamily base excision 
DNA repair protein 
SH2 domain Ribosomal protein S2 Cell division protein 
SH3 domain WW domain XPG N-terminal domain 
TNFR/NGFR cysteine-
rich region 
WD domain, G-beta 
repeat 
PAC motif 
Immunoglobulin 
domain 
Ribosomal protein S8 XPG I-region 
Myosin head (motor 
domain) 
Ribosomal protein 
S13/S18 
PAS domain 
Protein kinase domain MutS domain V GrpE 
RNA recognition 
motif. (a.k.a. RRM, 
RBD, or RNP domain) 
FHA domain F-actin capping protein, beta subunit 
Thrombospondin type 
1 domain 
AMP-binding enzyme DNA mismatch repair protein, C-
terminal domain 
Zinc finger, C2H2 type HMG (high mobility 
group) box 
Casein kinase II regulatory subunit 
Zinc finger, C3HC4 
type (RING finger) 
TPR Domain NNMT/PNMT/TEMT family 
Ligand-binding 
domain of nuclear 
hormone receptor 
DNA 
gyrase/topoisomerase IV, 
subunit A 
mRNA capping enzyme, catalytic 
domain 
Zinc finger, C4 type 
(two domains) 
Death domain LSM domain 
TCP-1/cpn60 
chaperonin family 
SAM domain (Sterile 
alpha motif) 
Skp1 family, dimerisation domain 
Carboxylesterase HRDC domain V-type ATPase 116kDa subunit family 
Calcineurin-like 
phosphoesterase 
Ribosomal protein L13 GAF domain 
Cyclophilin type 
peptidyl-prolyl cis-
trans isomerase 
Acetyltransferase 
(GNAT) family 
MutS domain I 
Hsp90 protein IQ calmodulin-binding 
motif 
Toprim domain 
DNA gyrase B RasGEF domain Putative snoRNA binding domain 
ATP:guanido Guanine nucleotide DIL domain 
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phosphotransferase, C-
terminal catalytic 
domain 
exchange factor for Ras-
like GTPases; N-terminal 
motif 
Glucocorticoid 
receptor 
Histidine kinase-, DNA 
gyrase B-, and HSP90-
like ATPase 
ATP:guanido phosphotransferase, N-
terminal domain 
Progesterone receptor Myosin N-terminal SH3-
like domain 
Proliferating cell nuclear antigen, C-
terminal domain 
Coatomer WD 
associated region 
Cdc37 family MH2 domain 
Helicase associated 
domain (HA2) 
Peptidase C1-like family Endonuclease/Exonuclease/phosphatase 
family 
MutS domain II BAR domain mRNA capping enzyme, C-terminal 
domain 
MutS family domain 
IV 
Tubulin-tyrosine ligase 
family 
Skp1 family, tetramerisation domain 
MutS domain III MH1 domain SNARE domain 
Protein of unknown 
function (DUF933) 
RWD domain Coatomer (COPI) alpha subunit C-
terminus 
CW-type Zinc Finger HD domain  
 
The death domain (DD, highlighted in yellow) was among the identified potential 
interacting partners for hPDK4. The death domain family of proteins is known to play 
an important role in apoptosis/ programmed cell death (Desaghner and Martinou, 
2000 and Kannan and Jain, 2000). The interweaver database was then used to identify 
the death domain proteins that are predicted to interact with PDK4. An excerpt of the 
results from this exercise is shown in Table 6.  
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Table 6. Four of the 24 DD proteins that were predicted to be potential interacting 
partners for hPDK4. 
Protein name Accession 
number 
Function(s) 
1. Death domain 
containing protein 
CRADD 
P78560 (1). Apoptotic adaptor molecule specific for 
caspase-2 and fasl/tnf receptor-interacting protein 
rip 
(2) In the presence of rip and tradd, raidd recruits 
caspase-2 to the tnf-1signalling complex 
2.  FAS-associating 
death domain 
containing protein 
(FADD) 
P13158 (1) It interacts with the death domain on Fas and 
initiates apoptosis 
(2) Apoptotic adaptor molecule that recruits 
caspase-8 or caspase-10 to the activated Fas 
(CD95) or TNFR-1 receptor 
(3) Active caspase-8 initiates the subsequent 
cascade of caspases (aspartate-specific cysteine 
proteases) mediating apoptosis. 
3. Nuclear factor NF-
kappa-B p105 subunit 
P19838 Have dual functions such as cytoplasmic retention 
of attached NFκB proteins and generation of p52 
by a cotranslational processing 
p52 binds to the kappa-B consensus sequence 5’-
GGRNNYYCC-3’, located in the enhancer region 
of genes involved in immune response and acute 
phase reactions. 
4. Nuclear factor NF-
kappa-B p100/p49 
subunit 
 
Q00653 Dual functions such as cytoplasmic retention of 
attached NFκB proteins and generation of p50 by a 
cotranslational processing. 
 
 
 
24 death domain containing proteins were identified as potential partners for hPDK4. 
Of these 24 proteins, we showed 4 in table 6. These proteins are known to play a 
crucial role in apoptosis. This suggested a relationship between PDK4 and apoptosis. 
In addition, several scientific publications have linked diabetes to apoptosis (Chen, 
2005 and Mandrup-Poulsen, 2003). We therefore hypothesised that PDK4 could be a 
link between diabetes and apoptosis, and thus propose to investigate the relationship 
between PDK4 and apoptosis. To explore this relationship, we focussed on one of the 
DD proteins, i.e. p100/p49.  
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3.1.2 Identification of the sequences in hPDK4 that have the potential to 
interact with NFκB subunits sequence that allows dimerization 
 
The p100/p49 subunit and other NFκB subunits have been shown to use conserved 
amino acids to interact with each other in-order to form homo or heterodimers 
(McKay and Cidlowski, 1999 and Huang et al., 1997). These amino acids are 
indicated in Figure 11 below. 
 
 
 
Figure 11. Amino acids of NFκB subunits involved in the dimer formation with other 
subunits. Pink boxes indicate key and conserved amino acid residues that are involved 
in the dimerization interface; red boxes represent amino acids contributing to the 
dimmer interface through polypeptide backbone; green boxes indicate the 
nonconserved residues in the dimer interface and purple box represents the nuclear 
localization at the c-terminus. Adapted from McKay and Cidlowski, 1999 and Huang 
et al., 1997 
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To examine whether human PDK4 (hPDK4) contains the ability to interact with 
NFκB subunits in particular p100/p49; we used ClustalW a sequence alignment 
program to examine whether PDK4 contains the conserved amino acids that are 
important for NFκB recognition. The results of this alignment are shown below in 
Figure 12.  
 
 
 
 
 
 
 
 
Figure 12. An alignment comparison between human PDK4 and NFκB subunits p50; 
p52 and p65. The sequences were aligned using clustalW program. Different colours 
indicate chemical properties of the specified amino acid residues. Amino acid residues 
in blocks indicates total conservation; yellow shading represents amino acids involved 
in the dimerization interface; blue shading represents amino acids contributing to the 
dimmer interface through polypeptide backbone and green shading demonstrates non-
conserved amino acids at the dimer interface. 
 
Three amino acids that are known to be important in NFκB subunit dimerization were 
conserved between NFκB subunits and hPDK4. These are lysine 214; cysteine 215 
and histidine 249 (on hPDK4). NFκB amino acids corresponding to hPDK4 Lysine 
214 and histidine 249 are involved in the direct dimer formation of the NFκB subunits 
through the side chain interactions, whereas those corresponding to cysteine 215 use 
 
P50   -----ASNLKIVRMDRTAGCVTGGEEIY----LLCDKVQKDDIQIRFYEEEENGGVWEGF 51 
P52   -----ASNLKISRMDKTAGSVRGGDEVY----LLCDKVQKDDIEVRFYEDDENG--WQAF 49 
P65   -----TAELKICRVNRNSGSCLGGDEIF----LLCDKVQKEDIEVYFTG---PG--WEAR 46 
PDK4  SDSQTGNPSHIGSIDPNCDVVAVVQDAFECSRMLCDQYYLSSPELKLTQVNGKFPDQPIH 240 
               :*  :: ...     :: :    :***:   .. :: :              
 
P50   GDFSPTDVHRQFAIVFKTPKYKDINITK------PASVFVQLRRK-SDLETSE------- 97 
P52   GDFSPTDVHKQYAIVFRTPPYHKPKIDR------PVTVFLQLKRK-RGGDVSD------- 95 
P65   GSFSQADVHRQVAIVFRTPPYADPSLQA------PVRVSMQLRRP-SDRELSE------- 92 
PDK4  IVYVPSHLHHMLFELFKNAMRATVEHQENQPSLTPIEVIVVLGKEDLTIKISDRGGGVPL 300 
        :  :.:*:    :*:..     .         *  * : * :     . *:        
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the polypeptide backbone to form the NFκB dimer. Interestingly, aspartic acid 216 
also showed total conservation between hPDK4 and NFκB subunits. This amino acid 
has not previously been shown to play a role in the NFκB subunit dimer formation. 
These findings suggest that hPDK4 may potentially interact with NFκB. 
 
3.1.3 Comparison between the amino acid sequence of human and rat PDK 
isoforms with NFκB dimerization sequence 
 
The protein sequences of the other hPDKs and rat PDKs (rPDKs) isoforms were 
compared with the NFκB interacting amino acid sequences. This alignment was to 
determine any conservation of the NFκB interacting sequence within these isoforms 
(Figure 13). The results showed conservation of certain amino acids among the PDKs 
with NFκB subunits. The amino acids lysine (214); cysteine (215) and aspartic acid 
(216) which are conserved in hPDK4 were also conserved in the other human PDK 
isoforms as well as the rat isoforms except for a glutamic acid substitution in both 
human and rat PDK3. The other amino acid that is of interest is histidine which is 
conserved in all NFκB subunits and only human and rat PDK4 and not in the other 
isoforms. The other amino acids which are involved in the dimerization of the NFκB 
subunits were not conserved in the other PDK isoforms of both human and rat origin.  
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Figure 13. An alignment comparison of both human and rat PDK isoforms and 
nuclear factor kappa-B p50; p52 and p65 subunit. The protein sequences were aligned 
using clustalW program. All PDK isoforms and NFκB protein sequences ware 
obtained from NIBI protein database. The accession numbers are as follows: human 
isoforms PDK4 (AH40239); PDK3 (XP_216091); PDK2 (NP_002602); PDK1 
(NP_002601); rat isoforms: PDK4 (NP_446003); PDK3 (XP_216091); PDK2 
(NP_110499); PDK1 (AAH89783) and NFκB subunits: p50 (P19838); p52 (Q00653) 
and p65 (CAA80524). Shaded area correlates to the ones above in Figure 11 and 12. 
 
 
 
 
 
 
hPDK2  LDRFYLSRISIRMLINQHTLIFDGS--TNPAHPKHIGSIDPNCNVSEVVKDAYDMAKLLC 212 
rPDK2  LDRFYLSRISIRMLINQHTLIFDGS--TNPAHPKHIGSIDPNCSVSDVVKDAYDMAKLLC 212 
hPDK4  LDRFYMNRISTRMLMNQHILIFSDS---QTGNPSHIGSIDPNCDVVAVVQDAFECSRMLC 215 
rPDK4  LDRFYMNRISTRMLMNQHILIFSDS---KTGNPSHIGSIDPNCDVVAVVEDAFECAKMLC 215 
hPDK3  LDRFYTNRISFRMLINQHTLLFGGD--TNPVHPKHIGSIDPTCNVADVVKDAYETAKMLC 208 
rPDK3  LDRFYTNRISFRMLINQHTLLFGGD--TNPAHPKHIGSIDPTCNVADVVKDAYETAKMLC 208 
hPDK1  LDRFYMSRISIRMLLNQHSLLFGGKGKGSPSHRKHIGSINPNCNVLEVIKDGYENARRLC 240 
rPDK1  LDRFYMSRISIRMLLNQHSLLFGGK--GSPSHRKHIGSINPNCDVVEVIKDGYENARRLC 238 
P50    -----ASNLKIVRMDRTAGCVTGGE-----------------------------EIYLLC 26 
P52    -----ASNLKISRMDKTAGSVRGGD-----------------------------EVYLLC 26 
P65    -----TAELKICRVNRNSGSCLGGD-----------------------------EIFLLC 26 
              .:.   : .      ...                                 ** 
 
hPDK2  DKYYMASPDLEIQEINAANSKQPIHMVYVPSHLYHMLFELFKNAMRATVESHESSL-ILP 271 
rPDK2  DKYYMASPDLEIQEVNATNATQPIHMVYVPSHLYHMLFELFKNAMRATVESHESSL-TLP 271 
hPDK4  DQYYLSSPELKLTQVNGKFPDQPIHIVYVPSHLHHMLFELFKNAMRATVEHQENQP-SLT 274 
rPDK4  DQYYLTSPELKLTQVNGKFPGQPIHIVYVPSHLHHMLFELFKNAMRATVEHQENRP-FLT 274 
hPDK3  EQYYLVAPELEVEEFNAKAPDKPIQVVYVPSHLFHMLFELFKNSMRATVELYEDRKEGYP 268 
rPDK3  EQYYLVAPELEVEEFNAKAPNKPIQVVYVPSHLFHMLFELFKNSMRATVELYEDKKEGYP 268 
hPDK1  DLYYINSPELELEELNAKSPGQPIQVVYVPSHLYHMVFELFKNAMRATMEHHANRG-VYP 299 
rPDK1  DLYYINSPELELEELNAKSPGQPIQVVYVPSHLYHMVFELFKNAMRATMEHHADKG-VYP 297 
P50    DKVQKDDIQIRFYEEEENGGVWEGFGDFSPTDVHRQFAIVFKTPKYKDINIT-------K 79 
P52    DKVQKDDIEVRFYEDDENG--WQAFGDFSPTDVHKQYAIVFRTPPYHKPKID-------R 77 
P65    DKVQKEDIEVYFTG---PG--WEARGSFSQADVHRQVAIVFRTPPYADPSLQ-------A 74 
       :       :: .               :  :.:.:    :*:..     .           
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3.1.4 Location of a possible interaction site of NFκB subunits in hPDK4 
 
Having identified the hPDK4 region that is similar to the dimerization sequence of 
NFκB subunits, we then proceeded to identify its location withing the 3 dimensional 
structure of hPDK4. To this end, the Swiss PDB viewer was used to locate the 
conserved amino acids in the structure of hPDK4 that was modelled based on the 
coordinates of the experimentally resolved structure of rat PDK2 (CSIR report no. 
CSIR/PBIOTECH/RN/01/1628/B, Steussy et al., 2001). The results (Figure 14) 
showed that the amino acids are situated on the region of hPDK4 which forms an 
interaction between hPDK4 and ADP molecule. The amino acids identified to be 
involved in the interaction are leucine (241); leucine (244); phenylalanine (242); 
histidine (236) and tyrosine (238). These residues are situated at the center of a cone-
shaped cavity formed between the α-helices and β-sheets of the C-terminal domain of 
the protein (Steussy et al., 2001). This C-terminal domain of PDK4 is known to be 
involved in the binding of nucleotides. In addition, this region is exposed to the 
outside and is solvent accessible thus suggesting interaction with other proteins is 
possible as well. The conserved amino acids lysine 214; cysteine 215; aspartic acid 
216, and histidine 249 that have been identified to potentially play a role in interaction 
of hPDK4 with NFκB subunits are also located in this region. These findings suggest 
that PDK4 may interact with p100/p49 through these amino acids. This also 
strengthens our hypothesis that PDK4 may interact with p100/p49. 
 
 
 
 
 
  60 
                                 
  
 
  
 
Figure 14. Rat PDK2 structures showing conserved amino acids to that of NFκB 
subunits. The amino acids are situated between the α-helices (shown in yellow) and β-
sheets (shown in red) of the C-terminal domain region of PDK structure. (A), Amino 
acids involved in the interaction between hPDK4 and ADP, these are leucine (241); 
leucine (244); phenylalanine (242); histidine (236) and tyrosine (238) (shown in a 
green large square). (B) ADP molecule (shown in a green box) bound to the C-
terminal domain of the PDK structure. (C) Interacting residues of NFκB subunits on 
hPDK4 structure, these are lysine 214, cysteine 215, aspartic acid 216, and histidine 
249. 
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3.2 Examination of the relationship between hPDK4 and apoptosis 
 
Having used computational methods to uncover the potential interaction between 
hPDK4 and death domain containing proteins in particular p100/p49, we then used 
molecular biology techniques and cell culture studies to examine the relationship 
between hPDK4 and apoptosis. In these experiments, HeLa cells and HepG2 cells 
were treated with agents that are known to induce apoptosis and these cells were then 
assessed for cell death, apoptosis and levels of hPDK4 mRNA. 
 
3.2.1 Induction of cell death by TNFα, Ceramide, and Linoleic acid 
 
TNFa, ceramide and Linoleic acid are known to induce apoptosis (Dichtl et al., 2002; 
Kim et al., 2005 and Lee et al., 2005). To establish the optimal concentration and time 
course at which these factors induce cell death, HeLa cells and HepG2 cells were 
treated with different concentrations of TNFα, C2-Ceramide, and Linoleic acid over a 
specified time period. The trypan blue exclusion method was used to determine the 
degree of death induced in these cells as described in the materials and methods 
section. The concentrations of inducers used were 20 and 50 ng/ml for TNFα (Figure 
15 and 16), 20 and 40 µM for C2-Ceramide (Figure 17 and 18) and 300 µM and 1 
µM for Linoleic acid (Figure 19 and 20). The cells were treated for 2, 4, 6, 24 and 48 
hours for each concentration. The controls were included for each time intervals 
where cells were grown in serum free media.  
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Figure 15. Cell viability assessments of HeLa and HepG2 cells that were treated with 
20 ng/ml TNFα concentration for different time points. Blue bars indicate Hela cells 
and the purple bars indicate Hep G2 cells. 
 
Both HeLa and HepG2 cell viability decreased with increasing time. At 48 hours of 
treatment with 20 ng/ml concentration of TNFa, there was a considerable increase in 
cell death in both HeLa and HepG2 cells.  
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Figure 16. Cell viability assessments of HeLa and HepG2 cells treated with 50 ng/ml 
TNFα concentration for different time points. Blue bars indicate Hela cells and the 
purple bars indicate Hep G2 cells. 
 
Increasing TNFα concentration to a 50 ng/ml in both the cell lines resulted in massive 
increase in cell death. After 6 hours, cell death was about 50 % and at 48 hours there 
was about 10 % cell viability. 
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Figure 17. Cell viability assessments of HeLa and HepG2 cells treated with 20 µM 
C2-Ceramide for different time points. Blue bars indicate Hela cells and the purple 
bars indicate Hep G2 cells.  
 
Lower concentrations of C2-Ceramide of 20 µM in both HeLa and HepG2 cell lines 
resulted in induction of cell death. After 48 hours there was a sharp increase in cell 
death to about 30 % cell viability.  
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Figure 18. Cell viability assessments of HeLa and HepG2 cells treated with 40 µM 
C2-Ceramide for different time points. Blue bars indicate Hela cells and the purple 
bars indicate HepG2 cells.  
 
A higher concentration of C2-Ceramide of 40 µM showed decrease cell viability 
mostly after 24 hours. At 48 hours there were very few viable cells particularly in 
HepG2 cells. 
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Figure 19. Cell viability assessments of HeLa and HepG2 cells were treated with 300 
µM concentration of Linoleic acid for different time points. Blue bars indicate Hela 
cells and the purple bars indicate Hep G2 cells.  
 
Treating both HeLa and HepG2 cells with 300 µM Linoleic acid also induced cell 
death to a higher extent in HepG2 cells when compared to HeLa cells.  
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Figure 20. Cell viability assessments of HeLa and HepG2 cells treated with 1 mM 
Linoleic acid for different time points. Blue bars indicate Hela cells and the purple 
bars indicate HepG2 cells.  
 
Cell viability was reduced more after 24 and 48 hours in both the HeLa and HepG2 
cells. 1mM Linoleic acid also induced cell death to a higher extent in HepG2 cells 
than in HeLa cells. 
 
These three factors TNFα, C2-Ceramide and Linoleic acid were shown to induce cell 
death at both the different concentrations used. The highest concentrations of the three 
demonstrated to be the optimal concentrations that resulted in induction of cell death 
that can be clearly measured with respect to exposure time. 
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3.2.2 Induction of apoptosis by TNFα, C2-Ceramide, and Linoleic acid  
 
To assess whether apoptosis contributes in the cell death that is induced by TNFa, C2-
Ceramide, and Linoleic acid, cells were treated with the optimal concentrations of 
these factors. Having observed that cell death is evident after 24 hours of cell 
treatment with these factors, cells were than treated for 24, 48 and 72 hours in order to 
assess apoptosis. Apoptosis was measured by using a DNA laddering assay as 
described in materials and methods. Results from these experiments are shown in 
Figure 21.  
 
     M      1      2       3      4      5       6      7      8      9     10     11    12 
 
 
Figure 21. Induction of DNA laddering in HeLa cells that were treated with TNFα, 
Linoleic acid and C2-Ceramide. Lane M was a DNA marker, 1000 base pair ladder. 
Lanes 1; 5 and 9 were controls which were not treated, 2; 3 and 4 were cells treated 
with 50ng/ml TNFα at 24; 48 and 72 hours respectively. Lanes 6; 7 and 8 were treated 
with 40 µM C2-Ceramide at the same above hours. Lanes 10; 11 and 12 were treated 
with 300 µM Linoleic acid at the same above conditions.  
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Cells that were grown in serum free media were used as controls. Cells treated with 
TNFα showed DNA laddering for all the time intervals. C2-Ceramide induced 
apoptosis after 48 and 72 hours, and Linoleic acid also induced DNA laddering after 
48 hours.  
 
3.3 The effect of TNFα, C2-Ceramide, and Linoleic acid on PDK4 mRNA 
expression levels  
3.3.1 Cloning of human PDK4 (hPDK4) into pGEM-T-Easy 
 
RT-PCR was performed to determine the effect of TNFα, C2-Ceramide and Linoleic 
acid on PDK4 mRNA expression. In order to achieve this objective we had to first 
optimize the two set of primers designed for RT-PCR. To do that hPDK4 cloned into 
pENTR vector was used as a template for PCR. The PCR results (Figure 22) 
confirmed the presence of two fragments differing in about 200 base pairs. The larger 
fragments (2 and 4) full length (FF) gene was ~ 1.3 kilo base (kb) and the smaller 
fragments (1 and 3) short length (FS) gene was ~ 1.1 kb. 
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  M        1   2    3    4 
  
 
 
Figure 22. PCR products for hPDK4. 
Lane M is a 1 kb ladder molecular weight marker from Fermentas, South Africa. Lane 
1 and 3 are PCR fragments containing short length (FS) hPDK4 gene without the 
mitochondrial leader sequence. Lanes 2 and 4 are PCR fragments containing full 
length hPDK4 gene.  
 
3.3.2 Confirmation of the inserts by restriction digestion 
 
The PCR fragments containing the full length and short length hPDK4 were cut from 
the 1% agarose gel after the right sizes. The fragments were purified using Promega 
gel purification kit according to the manufacturer’s instruction. The fragments were 
then ligated to ‘T’ overhangs of the pGEM-T-Easy vector using the ‘A’ overhangs on 
the fragments produced by the PCR BioTaq polymerase from New England Biolabs. 
Plasmid DNA was extracted from the positive clones and was linearized by digestion 
with Xho I and run on 1% agarose gel (Figure 23).  
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The results showed the expected fragments of about ~ 4.3 kb and 4.1 kb which 
represented the two clones with full and short length genes. The clones were further 
digested with Xho I and Not I and the results (Figure 24) confirmed the presence of 
the right inserts. 
 
 M          1      2 
 
 
 
Figure 23. Restriction analysis of the clones. 
Lane M is a 1 kb ladder molecular weight marker from Fermentas. Lane 1 is a 
restriction digested clone containing a full length insert with a size of ~ 4.3 kb. Lane 2 
is a clone containing a short length insert with a size of ~ 4.1 kb. Both the clones were 
linearized with Xho I restriction enzyme. 
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Figure 24. Restriction analysis of the inserts. 
Lane M is a 1 kb DNA ladder molecular weight marker from Fermentas. Lane 1 and 2 
are clones digested with Xho I and Not I to release the short length insert which is ~ 
1.1 kb in size. Lane 3 and 4 clones were also digested with Xho I and Not I to release 
the full length insert which is ~ 1.3 kb in size. Both Xho I and Not I were used 
because they were incorporated in the designed two set of primers to confirm the 
presence of the inserts.  
 
 
3.3 The effect of TNFα, C2-Ceramide and Linoleic acid on the PDK4 
mRNA expression levels  
 
3.3.1 Optimising conditions for the RT-PCR  
 
In order to examine whether there is a relationship between PDK4 and apoptosis, 
HepG2 cells were treated for 24, 48 and 72 hours with TNFα, C2-Ceramide, or 
Linoleic acid. Real time PCR was performed to determine the level of expression of 
3.0 kb 
1.5 kb 
1.0 kb 
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the PDK4 mRNA after treatment with these three factors. The RNA used was 
extracted from these cells as described in materials and methods. The first step to be 
done was to optimize for the concentration of the DNA template to be used and the 
primers as this is the most important step in RT-PCR. Different concentrations of the 
DNA were used and 100ng was identified as the suitable amount. Based on the above 
finding, 100ng of the treated samples was run on the RT-PCR and the results are 
shown in Figure 25.  
 
 
 
Figure 25. Amplification plot for the PCR amplification of PDK4 gene from HepG2 
cells after treatment with TNFα, C2-Ceramide and Linoleic acid over a 72 hour 
period. Different curves represented by different colours represent PCR amplicons of 
PDK4 genes. Dotted lines represent the threshold cycles (Ct) of each sample above 
the threshold line 
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The PCR efficiencies of the products varied from 7 and 73% which is below the 
accepted range of between 90-100%. The low efficiency values may have resulted due 
to the secondary structure formation, concentration of the product or the quality of the 
primers. The efficiencies increased with increasing treatment time of each inducer. 
The Ct values for all the samples were below 40 (Table 7) and this confirmed 
successful amplification of the product. The efficiencies increased with increasing 
treatment time of each inducer. The Ct values for all the samples were below 40 and 
this confirmed successful amplification of the product.  
 
Table 7. Efficiencies (%) and threshold cycle (Ct) values of the RT-PCR product  
Sample Time (hrs) Efficiency Ct 
Control (untreated) 24 16.47 17.22 
TNFα 24 3.40 15.73 
C2-Ceramide 24 6.57 18.59 
Linoleic acid 24 46.96 28.12 
Control (untreated) 48 37.21 23.62 
TNFα 48 40.47 26.91 
C2-Ceramide 48 39.25 32.81 
Linoleic acid 48 72.91 23.80 
Control (untreated) 72 49.23 24.32 
TNFα 72 43.59 27.78 
C2-Ceramide 72 39.58 31.44 
Linoleic acid 72 41.96 25.75 
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The melting curve for the treated samples was performed to determine whether the 
amplified gene hPDK4 is pure. The results are shown below in the melting curve in 
Figure 26. All the samples showed to have the melting temperature peaks for PDK4 
gene at 83˚C. However, there were some smaller peaks which indicated that the 
product was not very pure and this might have resulted due to contamination while 
preparing the samples for RT-PCR.  
 
 
 
Figure 26. Melting temperature profiles of PDK4 gene after HepG2 cells treatment 
with TNFα, C2-Ceramide and Linoleic acid over a 72 hour period. The melting 
temperature peaks for PDK4 gene were generated at 83˚ C.  
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3.3.2 Determination of the PDK4 mRNA expression levels 
 
To further determine the effect TNFα, C2-Ceramide and Linoleic acid have on the 
expression levels of the PDK4 mRNA; RT-PCR was performed using the 100ng 
cDNA concentration of each sample identified above after optimization. The 
expression was performed to compare the difference in the PDK4 mRNA expression 
levels in the HepG2 cells after treating with TNFα, C2-Ceramide and Linoleic acid for 
over 72 hour period. The control which is the untreated was used to serve as the 
reference point as well as the negative control which contained no cDNA. The 
standard curve was constructed by making serial dilutions of the PDK4 clone 
prepared earlier by cloning into pGEM-T-easy. The standard curve (Figure 27) was 
used to compare quantitatively the expression level between the treated samples and 
the untreated.  
 
 
Figure 27. A standard curve for real-time quantitation of PDK4 DNA. The serial 
dilutions of the control DNA (1000ng to 0.05ng) was performed for the construction 
of  standard curve. The PCR efficiency was 93% as indicated by the slope m= -0.27.  
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The PCR efficiency was obtained to be 93%. This was considered a good efficiency 
as it should lie between 90-100%. The slope of the graph showed a perfect doubling 
of the template as the value obtained was -0.27 which is close to -0.30 the expected 
slope. The quantitative graphs representing the fluorescence measured at each cycle 
for each sample were plotted. The graphs were plotted separately based on the 
treatment time for example after 24 hours (Figure 27); 48 hours (Figure 29) and 72 
hours (Figure 30). 
 
 
 
 
Figure 28. Quantitative graph of PDK4 gene after 24 hour treatments with the three 
inducers. Red graph represents the control; blue graph represents C2-Ceramide; green 
represents TNFα and yellow represents Linoleic acid. Dotted lines represent the 
threshold cycles (Ct) of each sample above the threshold line. 
 
A quantitation graph measures the fluorescence intensity against the threshold cycle. 
This is a representation of amount of products produced within few PCR cycles to 
Control 
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reach the threshold which means samples with more templates initially will require 
fewer cycles to reach threshold than samples with less template. The threshold cycle 
(Ct) of a sample is defined as the cycle at which the sample’s fluorescence trace 
crosses the threshold line. The results demonstrate the control graph to appear first in 
all the three experiments (Figure 28; Figure 29 and Figure 30) indicating there was 
more template and thus more products were produced.  
 
 
 
Figure 29. Quantitative graph of PDK4 gene after 48 hour treatments with the three 
inducers. Red graph represents the control; blue graph represents C2-Ceramide; green 
represents TNFα and yellow represents Linoleic acid. Dotted lines represent the 
threshold cycles (Ct) of each sample above the threshold line. 
 
Both TNFα and C2-Ceramide showed a similar downregulating effect on PDK4 
mRNA in all the three treatments. Linoleic acid did show a downregulation of PDK4 
mRNA but it was different from the two (Figure 29 and Figure 30).  
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Figure 30. Quantitative graph of PDK4 gene after 72 hour treatments with the three 
inducers. Red graph represents the control; blue graph represents C2-Ceramide; green 
represents TNFα and yellow represents Linoleic acid. Dotted lines represent the 
threshold cycles (Ct) of each sample above the threshold line. 
 
3.3.3 Relative quantitative expression levels of PDK4 mRNA 
 
 
Relative expression was performed to compare the difference in the PDK4 mRNA 
expression levels in the HepG2 cells after treating with TNFα, C2-Ceramide and 
Linoleic acid. The control which is the untreated was used as the reference point. The 
standard curve was used to quantify and compare the mRNA expression levels 
between the treated samples and the untreated which is the control. The comparison of 
the PDK4 mRNA expression between the control and the three factors known to 
Control 
(untreated) 
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induce apoptosis was conducted under three different time intervals of 24, 48 and 72 
hours (Table 8; 9 and 10). The same concentration of 100ng DNA of each sample 
was added. 
 
To determine the relative expression level of the PDK4 mRNA in absolute terms a 
formula was used, Relative Expression Level = 2ΔCt. The ΔCt is the difference in the 
Ct values for the different inducers compared (Table 8; 9 and 10). This formula 
compared the expression of PDK4 mRNA when treated with TNFα, C2-Ceramide and 
Linoleic acid on HepG2 cells. By using the above formula the reference mRNA will 
be represented by 1 which as a result will serve as the base from which an increase or 
a decrease in expression can be determined. After 24 hour treatment (Table 8) it was 
found that the there was a slight decrease in all the three inducers. Linoleic acid 
already showed a significant 10 fold decrease at this time interval compared to others.  
Although after 48 and 72 hours, Linoleic acid (Table 9 and 10) demonstrated a 
drastic increase in expression with increasing time well below the control indicating 
downregulation. TNFα indicated a steady but constant 3 fold decrease in PDK4 
expression level. The three factors indicated a clear decrease in the PDK4 mRNA 
expression levels compared to the control. 
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Table 8. Relative quantitative expression of PDK4 after 24 hour treatment 
 
Sample 
 
Efficiency (%) Threshold 
cycle (Ct) 
 
Relative 
expression level1 
Concentration 
(ng) 
Control  
(untreated) 
16.47 17.22  1644 
TNFα 
 
3.40 15.73 1.5 3190 
C2-Ceramide 
 
6.57 18.59 - 1.4 898.9 
Linoleic acid 
 
46.96 28.12 - 10 13.25 
1. The relative expression level of PDK4 mRNA was determined using the following 
formula: Relative expression level = 2 ΔCt 
 
 The 24 hours treatment results revealed TNFα to have reached the lowest threshold 
cycle (Table 8) first before the control. These results (Figure 31) demonstrated an 
increase in PDK4 mRNA levels when treated with TNF and a decrease when treated 
with C2-Ceramide and Linoleic acid.  
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Figure 31. Quantitative comparison of the PDK4 gene between the control 
(untreated) and the three inducers of apoptosis after treating for 24 hours.  
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Table 9. Relative quantitative expression of PDK4 after 48 hour treatment 
 
Sample 
 
Efficiency (%) Threshold 
cycle (Ct) 
Relative 
expression level1 
 
Concentration 
(ng) 
Control 
(untreated) 
37.21 23.62  97.11 
TNFα 
 
40.47 26.91 - 3.29 22.63 
C2-Ceramide 
 
39.25 32.81 - 9.19 1.665 
Linoleic acid 
 
72.91 23.8 - 0.18 89.8 
1. The relative expression level of PDK4 mRNA was determined using the following 
formula: Relative expression level = 2 ΔCt 
 
The TNFα results were not consistent with the treatment after 48 and 72 hours 
(Figure 32 and 33) as there was instead a decrease in the PDK4 mRNA levels. This 
strongly suggested that TNFα is downregulating PDK4 mRNA. C2-Ceramide also 
indicated to have a strong effect (Figure 32) on PDK4 mRNA as it showed to 
decrease further with increasing treatment time.  
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Figure 32. Quantitative comparison of the PDK4 gene between the control and the 
three inducers of apoptosis after 48 hour treatment. 
 
  83 
Table 10. Relative quantitative expression of PDK4 after 72 hour treatment 
 
Sample 
 
Efficiency (%) Threshold 
cycle (Ct) 
Relative 
expression level1 
 
Concentration 
(ng) 
Control  
(untreated) 
49.23 24.32  71.15 
TNFα 
 
43.59 27.78 - 3.5 15.45 
C2-Ceramide 
 
39.58 31.44 - 7.12 3.059 
Linoleic acid 
 
41.96 25.75 -1.4 37.82 
1. The relative expression level of PDK4 mRNA was determined using the following 
formula: Relative expression level = 2 ΔCt 
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Figure 33. Quantitative comparison of the PDK4 gene between the control and the 
three inducers of apoptosis after 72 hour treatment. 
 
Linoleic acid effect was not as effective as TNFα and C2-Ceramide. It did show 
suppression of the PDK4 mRNA but it was less compared with the other two factors. 
All the three known inducers of apoptosis, TNFα, C2-Ceramide and Linoleic acid 
demonstrated to a decrease in the PDK4 mRNA levels which means the three factors 
suppresses PDK4 expression levels. 
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CHAPTER 4 
 
4 Discussion 
 
 
4.1 Bioinformatics analysis of proteins that potentially interact with PDK4 
 
 
Understanding the regulation of PDK4 is important since it provides more 
opportunities for intervention in the treatment of type II diabetes which currently 
affects 6% of the world population and is reported to be growing at a rapid rate (Owen 
and Hattersley, 2001 and Bailey, 2000). Currently, the regulation of PDK4 has been 
studied primarily at the level of gene expression and interaction of the PDK protein 
with allosteric factors. Studies by Popov et al., (1993) indicated that PDK4 activity is 
also regulated by the interaction with its protein substrate pyruvate dehydrogenase 
complex (PDC). This, together with that are the many roles that protein-protein 
interaction is known to play in regulating target protein activity and cellular 
homeostasis (Sugden and Holness, 2003), inspired us to examine whether PDK4 
interacts with other proteins as well. To that end, the Interweaver database was used 
to uncover proteins that have domains predicted to interact with hPDK4. This 
revealed an extensive number of domains from a variety of protein families that could 
potentially interact with hPDK4 (Table 5) as well as specific proteins that could be 
involved (Table 6). The death domain (DD) protein is a highly conserved region of ~ 
80 amino acids which is found in proteins that are involved in apoptosis (Schlessinger 
and Ullrich, 1992). The major role of this domain is to connect together the proteins 
involved in apoptosis through hydrophilic intractions (Aravind et al., 1999 and Harper 
et al., 2003).  
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The findings mentioned above suggested a role for PDK4 in apoptosis.  This was very 
interesting since PDK4 was primarily associated with regulation of glucose clearance 
and diabetes, and not apoptosis.  A subsequent search of published literature revealed 
two papers that suggested a role for PDK in apoptosis.  Work reported by Roche and 
Hiromasa (2007) indicated that inhibition of PDK activity by pan-PDK inhibitors 
resulted in activation of PDC and induction of apoptosis in cancer cells that 
selectively convert glucose to lactate.  However, it is not clear from this study whether 
this effect is PDK isoform specific since the inhibitors did not differentiate between 
the different PDK isoforms.  However, results reported by Kim et al., (2006) 
demonstrated that over-expression of PDK1 rescued cells from hypoxia-induced 
apoptosis.  Whether PDK4 also plays the same role has not previously been 
demonstrated. 
 
The possible mechanism for involvement of PDK in apoptosis has not been defined.  
Interweaver database indicated that p100/p49, a subunit of NFκB was among the DD 
containing proteins identified to have the potential to interact with hPDK4 (Table 6).  
Numerous studies have provided compelling evidence that NFκB plays an important 
role in induction of apoptosis (Kim et al., 2005; Orange and Geha, 2003 and 
Vestergaard et al., 2005).  Interestingly, NFκB has been extensively linked to the 
development of insulin resistance and diabetes (Nunn et al., 2007; Chen et al., 2005; 
Schmid et al., 2006 and Alves et al., 2005).  However, interaction between NFκB and 
PDK4 has not been reported.  To address this, bioinformatics tools were further 
utilized.  To that end, ClustalW was used align the protein sequences of PDK4 and 
other NFκB subunits including p50 (representing p100/p49) that was retrieved from 
NCBI protein database in order to examine whether PDK4 contains sequence regions 
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that are known to be involved in NFκB subunit interactions.  The amino acid 
sequences on NFκB subunits responsible for interaction with other subunits were 
identified by Huang et al., (1997). These amino acids were classified into three 
categories: the conserved residues directly involved in dimerization; the non-
conserved residues; and the residues contributing to the dimer interface through 
polypeptide backbone contacts (Figure 11).  
 
The alignment of PDK4 and the NFκB subunits demonstrated conservation of certain 
amino acids responsible for the dimerization with other subunits.  These amino acids 
are (using hPDK4 nomenclature) lysine 214; cysteine 215; aspartic acid 216 and 
histidine 249 (Figure 12).  The total conservation of lysine 214; cysteine 215, and 
histidine 249, which are directly involved in the dimerization with other subunits, 
indicated a possibility for p100/p49 to interact with PDK4.  Aspartic acid 216 was 
also totally conserved, although its role in NFκB dimmer formation has not been 
previously identified, despite its location on a sequence that is known to be important 
in this process.  Interestingly, this region is also conserved in all the other isoforms of 
human and rat PDK (Figure 13). Currently the function of these three residues in the 
PDKs had not been defined.  What is known is that they form part of the α9 helix 
which forms part of the C-terminal domain.  The histidine residue at position 249 that 
was conserved between hPDK4 and NFκB subunits (Figure 13) was only conserved 
in both rat and human PDK4 and not in any other isoforms, perhaps indicating a 
differentiating role for PDK4 from other PDK isoforms.  
 
To locate the conserved amino acids on the hPDK4 structure Swiss Pdb Viewer 
program was used.  Human PDK4 structure was modelled based on the published rat 
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PDK2 coordinates.  The results showed the conserved amino acids to be located on 
the C-terminal end of hPDK4.  This region is highly conserved and made of α and β 
sheets folded together to form a heterodimer that contains the nucleotide binding site 
(Steussy et al., 2001).  These sheets are folded in such a way that they form uniform 
subdomains known as N box, G1 and G2 box and the G subdomains which are the 
ones involved in nucleotide binding (Bowker-Kinley and Popov, 1999).  The amino 
acid residues that are involved in interaction with NFκB subunits were situated around 
this area on PDK4 structure (Figure 14) where PDK4 binds the ADP molecules 
(Steussy et al., 2001 and Bao et al., 2004).  These nucleotides binding pockets are 
exposed outwards and are easily accessible. This suggests that the region is solvent 
accessible which makes it easy for the interaction with other proteins as well.  These 
findings strengthen the hypothesis that PDK4 may interact with p100/p49 through 
these amino acids. 
 
4.2 Examination of the relationship between hPDK4 and apoptosis  
4.2.1 Induction of apoptosis by TNFα, C2-Ceramide and Linoleic acid in 
Hela and Hep G2 cells 
The above discussed results suggest strongly that hPDK4 may have a role in 
apoptosis.  To further explore this hypothesis, cells in tissue culture were used to 
examine whether there is a relationship between hPDK4 and factors that are known to 
induce apoptosis.  These factors include TNFα, C2-Ceramide, and Linoleic acid (Mu 
et al., 2001, Lee et al., 2005, Bocca et al., 2007 and Lihui et al., 2007, and Haimovits-
Friedman et al., 1997).  Consistent with previously reported work, these factors 
induces cell death (Figures 14 – 19) and apoptosis (Figure 20) at defined doses and 
timeframes in Hela and HepG2 cells.  
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4.2.2 The effect of TNFα, C2-Ceramide and Linoleic acid on the level of 
PDK4 mRNA expression  
 
The effect of TNFα, C2-Ceramide and Linoleic acid on the PDK4 mRNA levels was 
investigated.  For this purpose, Hep G2 cells were treated with TNFα, C2-Ceramide 
and Linoleic acid at dosage and time period that had been previously determined to be 
suitable for induction of apoptosis.  Real-time PCR experiments performed on RNA 
extracted from these cells indicated that all these factors decreased the levels of 
hPDK4 mRNA to different degrees when compared to levels observed in control 
(untreated) cells. Linoleic acid had the least effect on PDK4 expression levels 
compared to the other two inducers.  TNFα and C2-Ceramide had nearly similar effect 
on the PDK4 mRNA expression levels.  The results showed by TNFα and C2-
Ceramide maybe due to the fact that TNFα uses ceramide as one of its down stream 
signaling molecules when it induces apoptosis (Lee et al., 2005 and Haimovits-
Friedman et al., 1997).  These findings support the hypothesis that PDK4 plays a role 
in apoptosis. 
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CHAPTER 5 
5 Conclusion  
 
The goal of this research was to explore potential interaction between PDK4 and other 
proteins in order to further understand how the activity of PDK4 is regulated and how 
this might impact on the development of insulin resistance and diabetes.  Analysis 
performed using computational methods uncovered numerous proteins that contained 
domains from several protein families that were predicted to interact with hPDK4.  
Among the families identified was the death domain containing protein family which 
is known to be important in apoptosis, suggesting a role for hPDK4 in apoptosis.  Of 
particular interest to us were the subunits of NFκB since NFκB is also known to play 
a role in insulin resistance and diabetes.  Further, computational analysis revealed that 
amino acids that are known to participate in the dimerization of NFκB subunits are 
also conserved between hPDK4 and NFκB, as well as in PDK isoforms.  Further, 
these amino acids are located in the solvent accessible region of PDK indicating 
accessibility to PDK substrates.  Results from these studies strongly indicate 
interaction between hPDK4 and NFκB and strongly suggest a role for hPDK4 in 
apoptosis.   
 
Our studies in Hela and HepG2 cells confirmed a relationship between hPDK4 and 
apoptosis.  These studies demonstrated that treatment of these cells with TNFα, C2-
Ceramide and Linoleic acid led to the induction of cell death and apoptosis, as well as 
reduction in levels of hPDK4 mRNA.  These results suggest an anti-apoptotic role for 
PDK4.  To further understand the underlying mechanism involved in the possible 
interaction between PDK4 and the subunits of NFκB and its involvement in apoptosis 
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more studies are required.  Over expression of hPDK4 would enable the examination 
of whether hPDK4 protects cells against the induction of apoptosis.  Likewise, it 
would be interesting to explore whether inhibition of hPDK4 by RNA interference or 
specific inhibitors results in induction of apoptosis in mammalian cells.  
Immunoprecipitation experiments would also confirm whether there is interaction 
between hPDK4 and any of the NFκB subunits.  Site directed mutagenesis of the 
conserved amino acids (on hPDK4) would also demonstrate their involvement in this 
interaction and their role in regulating apoptosis. 
 
We postulate that PDK4 interacts with p100 and phosphorylates it on serine residues. 
Phosphorylation of p100 by PDK4 prevents association of p100 with IKK and thus 
prevents the generation of p50 and the formation of a functional NFκB hetero- dimer 
between p50 and p65.  This therefore prevents induction of pro-apoptotic genes. 
Therefore induction of pro-apoptotic genes would require suppression of PDK4. 
Serine phosphorylation of signalling molecules has previously been shown to block 
signalling cascades and result in insulin resistance (Waraich et al., 2008, Xu et al., 
2008, Feng et al., 2008, Tremblay et al., 2007, Coba et al., 2004 and Takane et al., 
2001) as well as growth hormone resistance (Ahmed et al., 2005, Shumate et al., 
2005, Coba et al., 2004 and Takane et al., 2001).  Verification of this hypothesis with 
regard to the role of PDK4 in NFκB mediated signal transduction would require 
utilization of PDK4 kinase activity assays with p100 as substrate, to demonstrate that 
PDK4 results in phosphorylation of p100. Further, phosphorylation sites would have 
to be mapped on p100 and the role of phosphorylation of these sites in signal 
transduction would have to be elucidated. Studies examining the impact of over-
expression of PDK4 on apoptosis would add tremendous value in verifying our 
hypothesis. The model we are postulating is demonstrated in figure 34 below. 
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Figure 34. The schematic diagram indicating the possible role of PDK4 in preventing 
non-classical NFκB signalling. (A) The classical NFκB signalling pathways and (B) 
Blocking of the non-classical NFκB pathway by PDK4.  CM stands for cell 
membrane, R stands for receptor and N stands for nucleus. RH stands for Rel 
homology domain. Oval P stands for the phosphorylation event that enables signalling 
and star P indicates the possible phosphorylation event that would prevent normal 
NFκB signalling.  Crossed arrows indicate blocked events and un-crossed arrows 
indicate events that are permitted to occur. 
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